Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Mar. 09, 2017	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	STRATA Skin Sciences, Inc.
Entity Central Index Key	0001051514
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 5,093,146
Entity Common Stock, Shares Outstanding		10,909,490
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 3,928	$ 3,303
Restricted cash	0	15
Accounts receivable, net	3,390	4,068
Inventories	2,817	4,128
Prepaid expenses and other current assets	617	465
Total current assets	10,752	11,979
Property and equipment, net	10,180	13,851
Patents and licensed technologies, net	6,272	7,247
Other intangible assets, net	7,140	7,980
Goodwill	8,803	8,928
Other assets	46	94
Total assets	43,193	50,079
Current liabilities:
Note payable	339	299
Current portion of long-term debt	1,714	0
Accounts payable	1,853	4,446
Other accrued liabilities	1,992	2,161
Deferred revenues	235	173
Total current liabilities	6,133	7,079
Long-term liabilities:
Long-term debt, net	9,752	9,851
Senior secured convertible debentures, net	12,028	9,839
Warranty liability	105	7,042
Deferred tax liability	359	119
Other liabilities	97	62
Total liabilities	28,474	33,992
Commitments and Contingencies
Stockholders' equity:
Preferred Stock, $.10 par value, 10,000,000 shares authorized; 6,000 and 6,505 shares issued and outstanding, respectively	1	1
Common Stock, $.001 par value, 150,000,000 shares authorized; 10,834,490 and 10,283,393 shares issued and outstanding, respectively	11	10
Additional paid-in capital	225,280	223,315
Accumulated deficit	(210,575)	(207,240)
Accumulated other comprehensive income	2	1
Total stockholders' equity	14,719	16,087
Total liabilities and stockholders' equity	$ 43,193	$ 50,079

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current liabilities:
Accounts payable, related parties	$ 0	$ 74
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	6,000	6,505
Preferred stock, shares outstanding (in shares)	6,000	6,505
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	10,834,490	10,283,393
Common stock, shares outstanding (in shares)	10,834,490	10,283,393

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) [Abstract]
Revenues	$ 31,757	$ 18,495
Cost of revenues	12,636	13,719
Gross profit	19,121	4,776
Operating expenses:
Engineering and product development	1,929	2,029
Selling and marketing	13,152	9,194
General and administrative	7,637	10,028
Total operating expenses	22,718	21,251
Operating loss before other income (expense), net	(3,597)	(16,475)
Other income (expense), net:
Interest expense, net	(4,900)	(10,200)
Change in fair value of warrant liability	5,396	1,814
Other income, net	21	33
Other income (expense), net	517	(8,353)
Loss before income taxes	(3,080)	(24,828)
Income tax expense	255	119
Net loss	(3,335)	(24,947)
Deemed dividend related to warrant modification	0	(2,962)
Net loss attributable to common stockholders	$ (3,335)	$ (27,909)
Net loss per share:
Basic (in dollars per share)	$ (0.31)	$ (3.27)
Diluted (in dollars per share)	$ (0.75)	$ (3.27)
Shares used in computing net loss per share:
Basic (in shares)	10,595,068	8,536,699
Diluted (in shares)	11,578,573	8,536,699
Other comprehensive income (loss):
Foreign currency translation adjustments	$ 1	$ 1
Comprehensive loss	$ (3,334)	$ (27,908)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock [Member] Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Total
Beginning balance at Dec. 31, 2014	$ 1	$ 6	$ 194,562	$ (182,293)	$ 0	$ 12,276
Beginning balance (in shares) at Dec. 31, 2014	11,787	6,037,232
Stock-based compensation	$ 0	$ 0	1,753	0	0	1,753
Stock-based compensation (in shares)	0	100,000
Conversion of convertible preferred stock	$ 0	$ 2	(2)	0	0	0
Conversion of convertible preferred stock (in shares)	(5,282)	2,059,455
Conversion of senior secured convertible debentures	$ 0	$ 2	4,813	0	0	4,815
Conversion of senior secured convertible debentures (in shares)	0	2,086,706
Discount on senior secured convertible debentures	$ 0	$ 0	27,300	0	0	27,300
Reclassification of warrant liability to stockholders' equity	0	0	(5,399)	0	0	(5,399)
Deemed dividend contribution to additional paid-in capital	0	0	2,962	0	0	2,962
Deemed dividend distribution from additional paid-in capital	0	0	(2,962)	0	0	(2,962)
Warrants issued in connection with debt	0	0	321	0	0	321
Registration costs	0	0	(33)	0	0	(33)
Other comprehensive income	0	0	0	0	1	1
Net loss	0	0	0	(24,947)	0	(24,947)
Ending balance at Dec. 31, 2015	$ 1	$ 10	223,315	(207,240)	1	16,087
Ending balance (in shares) at Dec. 31, 2015	6,505	10,283,393
Stock-based compensation	$ 0	$ 0	113	0	0	113
Stock-based compensation (in shares)	0	0
Conversion of convertible preferred stock	$ 0	$ 0	0	0	0	0
Conversion of convertible preferred stock (in shares)	(505)	196,686
Conversion of senior secured convertible debentures	$ 0	$ 1	264	0	0	265
Conversion of senior secured convertible debentures (in shares)	0	354,411
Reclassification of warrant liability to stockholders' equity	$ 0	$ 0	1,541	0	0	1,541
Warrants issued in connection with debt	0	0	47	0	0	47
Other comprehensive income	0	0	0	0	1	1
Net loss	0	0	0	(3,335)	0	(3,335)
Ending balance at Dec. 31, 2016	$ 1	$ 11	$ 225,280	$ (210,575)	$ 2	$ 14,719
Ending balance (in shares) at Dec. 31, 2016	6,000	10,834,490

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash Flows From Operating Activities:
Net loss	$ (3,335)	$ (24,947)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,366	4,051
Provision for doubtful accounts	120	20
Stock-based compensation	113	1,753
Deferred tax provision	240	119
Loss on disposal of property and equipment	124	0
Impairment of long-lived assets	0	920
Amortization of debt discount	2,473	8,479
Amortization of deferred financing costs	200	391
Inventory write-offs	0	4,818
Gain on the change in fair value of the warrant liability	(5,396)	(1,814)
Changes in operating assets and liabilities:
Accounts receivable	558	(186)
Inventories	1,311	(508)
Prepaid expenses and other assets	224	(139)
Accounts payable and accrued expenses	(2,605)	542
Other accrued liabilities	(169)	92
Other liabilities	36	(80)
Deferred revenues	62	(81)
Net cash provided by (used in) operating activities	322	(6,570)
Cash Flows From Investing Activities:
Payment for Lasers placed-in-service, net	(1,008)	(1,689)
Purchases of property and equipment	0	(35)
Restricted cash	15	(15)
Acquisition costs, net of cash received	125	(42,500)
Net cash used in investing activities	(868)	(44,239)
Cash Flows From Financing Activities:
Proceeds from convertible debentures	0	32,500
Repayment of convertible debentures	0	(103)
Proceeds from senior notes	0	10,000
Repayment of senior notes	0	(10,000)
Proceeds from long-term debt	1,500	10,500
Payments on notes payable	(333)	(93)
Registration costs	0	(134)
Net cash provided by financing activities	1,167	42,670
Effect of exchange rate changes on cash	4	8
Net increase (decrease) in cash and cash equivalents	625	(8,131)
Cash and cash equivalents, beginning of period	3,303	11,434
Cash and cash equivalents, end of period	3,928	3,303
Supplemental information:
Cash paid for interest	2,054	1,188
Supplemental information of non-cash investing and financing activities:
Modification of warrants recorded as a deemed dividend	0	2,962
Conversion of senior secured convertible debentures into common stock	265	4,815
Reclassification of property and equipment to inventory, net	0	107
Reclassification of warrants to equity	1,541	(5,399)
Recognition of debt discount and beneficial conversion feature on long-term debt	0	27,300
Recognition of warrants issued with term note credit facility as debt discount	47	321
Prepaid insurance financed with notes payable	372	334
Recognition of warrants issued in connection with financings	$ 0	$ 2,958

The Company

12 Months Ended

Dec. 31, 2016

The Company [Abstract]

The Company

Note 1

The Company:

Background

STRATA Skin Sciences, Inc. (and its subsidiary) ("STRATA" or "we" or the "Company") is a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders. In June 2015 the Company completed the acquisition of the XTRAC Excimer Laser and the VTRAC Excimer Lamp businesses which included a subsidiary in India. The XTRAC® and VTRAC® products are FDA cleared devices for the treatment of psoriasis, vitiligo and other skin disorders. The purchase price was $42,500 plus the assumption of certain business-related liabilities. (See Note 2, Acquisition.)

The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC received FDA clearance in 2000 and has since become a recognized treatment among dermatologists. The system delivers targeted 308um ultraviolet light to affected areas of the skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. As of December 31, 2016, there were 775 XTRAC systems placed in dermatologists' offices in the United States under the Company's recurring revenue business model. The XTRAC systems employed under the recurring revenue model generate revenue on a per procedure basis. The per-procedure charge is inclusive of the use of the system and the services provided by the Company to the customer which includes system maintenance, reimbursement support service and participation in the direct to patient marketing programs employed by the Company. The XTRAC system's use for psoriasis is covered by nearly all major insurance companies, including Medicare. The VTRAC Excimer Lamp system, offered in addition to the XTRAC system internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system.

Liquidity

As of December 31, 2016, the Company had an accumulated deficit of $210,575, and until 2016, had incurred losses and negative cash flows from operations since inception. To date, the Company has dedicated most of its financial resources to research and development, sales and marketing, and general and administrative expenses.

The Company has been dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. Management believes that its cash and cash equivalents as of December 31, 2016 combined with the anticipated revenues from the sale of the Company's products will be sufficient to satisfy its working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations through the next twelve months following the filing of this Form 10-K.

On October 25, 2016, we were notified by NASDAQ that NASDAQ had granted us an extension of the deadline to April 24, 2017 to demonstrate compliance with NASDAQ's continued listing requirements. We will continue to monitor the closing bid price for our common stock and to assess our options for maintaining the listing of its common stock on the NASDAQ Capital Market in light of the Notice. Failure to maintain the listing of our common stock on the NASDAQ Capital Market would lead to an event of default under the debentures issued in our 2015 financing. Also, if delisting were to occur, selling our common stock could be more difficult because smaller quantities of shares would likely be bought and sold, transactions could be delayed, and security analysts' coverage of us may be reduced. Furthermore, while we believe that our common stock would trade on the OTC Bulletin Board, we would lose various advantages attendant to listing on a national securities exchange, including but not limited to, eligibility to register the sale or resale of our shares on Form S-3 and the automatic exemption from registration under state securities laws for exchange-listed securities, which could have a negative effect on our ability to raise funds. Additionally it would be deemed a default under the 2015 debentures and a breach of our affirmative covenants and therefore an event of default under our financing documents with Midcap. If there is an event of default, the 2015 debentures and the term note could be due immediately and would be classified as a current liability.

As one approach to curing the listing deficiency, we have asked the Shareholders to approve a reverse stock-split of up to 1 for 10 of our common stock. We have scheduled the meeting for March 29, 2017 and we cannot assure you that we will have the necessary quorum to hold a vote on the proposal, or that if we do have a quorum that there will be a majority of shares cast in favor of authorizing the company to effect a reverse split.

Basis of Presentation:

Accounting Principles

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP").

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.

Reclassification

Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have material impact on the Company's equity, net assets, results of operations or cash flows.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the US requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of December 31, 2016, the more significant estimates include (1) revenue recognition, in regards to deferred revenues and valuation allowances of accounts receivable, (2) the fair value of assets acquired and liabilities assumed in the business combination, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards, (5) the valuation allowance related to deferred tax assets and (6) the fair value of financial instruments, including derivative instruments.

Revenue Recognition

The Company recognizes revenues from product sales when the following four criteria have been met: (i) the product has been delivered and the Company has no significant remaining obligations; (ii) persuasive evidence of an arrangement exists; (iii) the price to the buyer is fixed or determinable; and (iv) collection is reasonably assured. Revenues from product sales are recorded net of provisions for expected returns and cash discounts.

The Company ships most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will be granted FOB destination terms. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured and included in deferred revenues until that time.

For revenue arrangements with multiple deliverables within a single, contractually binding arrangement (usually sales of products with separately priced extended warranty), each element of the contract is accounted for as a separate unit of accounting when it provides the customer value on a stand-alone basis and there is objective evidence of the fair value of the related unit.

The Company has two distribution channels for its phototherapy treatment equipment. The Company either (i) places its lasers in a physician's office (at no charge to the physician), and generally charges the physician a fee for an agreed upon number of treatments or (ii) sells its lasers through a distributor or directly to a physician. In some cases, the Company and the customer stipulate to a quarterly or other periodic target of procedures to be performed, and accordingly revenue is recognized ratably over the period.

When the Company places a laser in a physician's office, it generally recognizes revenue based on the number of patient treatments performed, or purchased under a periodic commitment, by the physician. Amounts collected with respect to treatments to be performed through laser-access codes that are sold to physicians free of a periodic commitment, but not yet used, are deferred and recognized as a liability until the physician performs the treatment. Unused treatments remain an obligation of the Company because the treatments can only be performed on Company-owned equipment. Once the treatments are performed, this obligation has been satisfied.

The Company defers substantially all revenue from sales of treatment codes ordered by its customers within the last two weeks of the period in determining the amount of procedures performed by its physician-customers. Management believes this approach closely approximates the actual amount of unused treatments that existed at the end of a period.

Cash and Cash Equivalents

The Company invests its excess cash in highly liquid short-term investments. The Company considers short-term investments that are purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consisted of cash and money market accounts at December 31, 2016 and 2015.

Accounts Receivable

The majority of the Company's accounts receivable are due from physicians, distributors (international) and other entities in the medical field. Accounts receivable are most often due within 30 to 90 days and are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company's previous loss history, the customer's current ability to pay its obligation to the Company and available information about their credit risk, and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are considered uncollectible, and payments subsequently received on such receivables are credited to the bad debt expense. The Company does not recognize interest accruing on accounts receivable past due. The allowance for doubtful accounts were $135 and $45 at December 31, 2016 and 2015, respectively.

Inventories

Inventories are stated at the lower of cost or market. Cost is determined to be purchased cost for raw materials and the production cost (materials, labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods. For the Company's products, cost is determined on the first-in, first-out method. Throughout the laser manufacturing process, the related production costs are recorded within inventory. Work-in-process is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.

The Company's equipment for the treatment of skin disorders (e.g. the XTRAC) will either (i) be placed in a physician's office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser, whether for sale or for placement, is accumulated in inventory.

Reserves for slow moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trends. As of December 31, 2016 reserves on inventory were $257. During the year ended December 31, 2015, the Company recorded a write-down of $4,818 toward the remaining inventory value of the MelaFind® systems, raw materials and components. (See Note 3, Inventories.)

Property, Equipment and Depreciation

Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Excimer lasers-in-service are depreciated on a straight-line basis over the estimated useful life of five years. For other property and equipment, depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, primarily three to seven years for computer hardware and software, furniture and fixtures, and machinery and equipment. Leasehold improvements are amortized over the lesser of the useful lives or lease terms. Expenditures for major renewals and betterments to property and equipment are capitalized, while expenditures for maintenance and repairs are charged as an expense as incurred. Upon retirement or disposition, the applicable property amounts are deducted from the accounts and any gain or loss is recorded in the condensed consolidated statements of comprehensive loss. Useful lives are determined based upon an estimate of either physical or economic obsolescence or both.

Management evaluates the realizability of property and equipment based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. During the year ended December 31, 2015, the Company recorded a write-down of $920 on the remaining net book value of the MelaFind systems that were part of property and equipment (see Impairment of Long-Lived Assets and Intangibles).

Patent Costs and Licensed Technologies

Costs incurred to obtain or defend patents and licensed technologies are capitalized and amortized over the shorter of the remaining estimated useful lives or eight to 12 years. Core technology and product technology were recorded in connection with the asset purchase on June 22, 2015 and are being amortized on a straight-line basis over ten years for core technology and five years for product technology. (See Note 5, Patent and Licensed Technologies).

Other Intangible Assets

Other intangible assets were recorded in connection with the asset purchase on June 22, 2015. The assets that were determined to have definite useful lives are being amortized on a straight-line basis over ten years. Such assets primarily include customer relationships and trademarks. (See Note 7, Other Intangible Assets).

Accounting for the Impairment of Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually in December of each year in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit's carrying amount exceeds its fair value, referred to as a "step zero" approach. If, based on the review of the qualitative factors, we determine it is not more likely than not that the fair value of a reporting unit is less than its carrying value, we would bypass the two-step impairment test. If we conclude that it is more likely than not that a reporting unit's fair value is less than its carrying amount, we would perform the first step ("step one") of the two-step impairment test. Step 1 compares the fair value of the Group's reporting units to which goodwill was allocated to their carrying values. If the fair value of the reporting unit exceeds its carrying value, no further analysis is necessary. The reporting unit fair value is based upon consideration of various valuation methodologies, including guideline transaction multiples, multiples of current earnings, and projected future cash flows discounted at rates commensurate with the risk involved. If the carrying amount of the reporting unit exceeds its fair value, Step 2 must be completed to quantify the amount of impairment. Step 2 calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit, from the fair value of the reporting unit as determined in Step 1. The implied fair value of goodwill determined in this step is compared to the carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss, equal to the difference, is recognized. There was no impairment of goodwill as of December 31, 2016.

Impairment of Long-Lived Assets and Intangibles

Long-lived assets, such as property and equipment, and definite-lived intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the undiscounted cash flows attributable to the asset. If the carrying amount of an asset exceeds its undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds its fair value of the asset. During the year December 31, 2015 the Company recorded a write-down of $920 on the remaining net book value of the MelaFind systems that were part of property and equipment. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposed group classified as discontinued operations are presented separately in the appropriate asset and liability sections of the balance sheet. There were no impairments recorded as of December 31, 2016 related to any of the Company's intangible assets.

Functional Currency

The currency of the primary economic environment in which the operations of the Company are conducted is the US dollar ("$" or "dollars"). Substantially all of the Company's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar.

For foreign currency transactions included in the statement of comprehensive loss, the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the transaction of such balances are carried to financing income or expenses.

Assets and liabilities of the foreign subsidiary, whose functional currency is its local currency are translated from its functional currency to U.S. dollars at the balance sheet date exchange rate. Income and expense items are translated at the average rate of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive loss.

Fair Value Measurements

The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification 820, Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
	•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

The Company's recurring fair value measurements at December 31, 2016 and 2015 are as follows:

	Fair Value as of December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 12)	$	105	$	-	$	-	$	105


	Fair Value as of December 31, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 12)	$	7,042	$	-	$	-	$	7,042

The fair value of cash and cash equivalents are based on their respective demand value, which are equal to the carrying value. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of the Company's warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures. The carrying value of all other short-term monetary assets and liabilities is estimated to be approximate to their fair value due to the short-term nature of these instruments. The Company assessed its convertible debentures and long-term debt and determined that the fair value of total debt was $20,082 as of December 31, 2016. As of December 31, 2015 the fair value of total debt approximated the recorded value of $15,958.

Several of the warrants outstanding as of December 31, 2016 ad 2015 have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company and other warrants contain full ratchet provisions that reduce the exercise price of the warrants in the event of a transaction resulting in the issuance of equity below the current price of the warrants. Therefore these warrants are classified as derivatives. These warrants have been recorded at their fair value using a binomial option pricing model and will be recorded at their respective fair value at each subsequent balance sheet date. See Note 12, Warrants, for additional discussion.

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities and Other liabilities on the balance sheet. The activity in the warranty accrual during the years ended December 31, 2016 and 2015 is summarized as follows:

	December 31,
	2016			2015

Accrual at beginning of year	$	226		$	48
Acquired in asset purchase		-			265
Additions charged to warranty expense		196			98
Expiring warranties/claimed satisfied		(307	)		(185	)
Total		115			226
Less: current portion		(102	)		(168	)
	$	13		$	58

Product Development Costs

Costs of research, new product development and product redesign are charged to expense as incurred in engineering and product development.

Advertising Costs

Advertising costs are charged to expenses as incurred. Advertising expenses amounted to approximately $4,389 and $2,500 for the years ended December 31, 2016 and 2015, respectively.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized.

The Company accounts for uncertain tax positions in accordance with an amendment to ASC Topic 740-10, Income Taxes (Accounting for Uncertainty in Income Taxes), which clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position can be recognized in the financial statements only if the position is "more-likely-than-not" to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the "more-likely-than-not" threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded.

Concentration of credit risks

Financial instruments which subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The carrying amounts of these instruments approximate fair value due to their short-term nature. The Company deposits cash and cash equivalents in major financial institutions in the US. The Company performs periodic evaluations of the relative credit standing of these institutions. The Company is of the opinion that the credit risk in respect of these balances is immaterial. In addition, the Company performs an ongoing credit evaluation and establishes an allowance for doubtful accounts based upon factors surrounding the credit risk of customers (see also Accounts receivable above).

With the exception of the Company's international distributor, as described in Note 18, Significant Customer Concentrations, the balance of the Company's trade receivables do not represent a substantial concentration of credit risk. Most of the Company's sales are generated in North America, to a large number of customers. Management periodically evaluates the collectability of the trade receivables to determine the amounts that are doubtful of collection and determine a proper allowance for doubtful accounts.

Earnings Per Share

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period and their potential diluted effect is considered using the treasury method.

For the year ended December 31, 2016 diluted earnings per common share are computed by the numerator effected by the gain on the change in fair value of the warrant liability and the denominator is increased to include the number of additional potential common shares from the warrants underlying the warrant liability.

Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the year ended December 31, 2016:

	Year Ended December 31, 2016

Net loss	$	(3,335	)
Gain on the change in fair value of the warrant liability		(5,396	)
Diluted loss	$	(8,731	)

Weighted average number of common and common equivalent shares outstanding:
Basic number of common shares outstanding		10,595,068
Dilutive effect of warrants		983,505
Diluted number of common and common stock equivalent shares outstanding		11,578,573

For the year ended December 31, 2015, diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive.

Potential common stock equivalents outstanding as of December 31, 2016 and 2015 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows:

		December 31,
	2016		2015
Common stock equivalents of convertible debentures	46,105,715		46,435,127
Common stock purchase warrants	12,033,098		16,729,362
Common stock equivalents of convertible preferred stock	2,339,180		2,535,866
Common stock options	4,503,522		2,684,352
Total	64,981,515		68,384,707

The convertible debenture shares, warrant shares (except for those related to the gain) and option shares were excluded due to their effect are anti-dilutive for the years ended December 31, 2016 and 2015.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation – Stock Compensation. Under the fair value recognition provision of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award that is ultimately expected to vest and is recognized as operating expense over the applicable service period of the stock award using the graded vesting method.

Adoption of New Accounting Standards

In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" (Subtopic 835-30). ASU No. 2015-03 provides guidance that will require debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, in the same manner as debt discounts, rather than as an asset. The standard was effective for reporting periods beginning after December 15, 2015 and early adoption was permitted. The Company adopted this ASU effective January 1, 2016. (See Note 9, Convertible Debt.)

In September 2015, the FASB issued ASU No. 2015-16, "Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments." The amendments in ASU 2015-16 require that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, rather than retrospectively adjusting amounts previously reported. The amendments require that the acquirer record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. Effective for public business entities for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments should be applied prospectively to adjustments to provisional amounts that occur after the effective date with earlier application permitted for financial statements that have not been issued. The adoption of this ASU did not have a significant impact on the condensed consolidated financial statements.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provides guidance on management's responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provides guidance related to the required disclosures as a result of management evaluation. The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of the new guidance did not impact the Company's results of operations, cash flows or financial condition.

Recently Issued Accounting Standards

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), to simplify various aspects of the accounting and presentation of share-based payments, including the income tax effects of awards and forfeiture assumptions. Currently, tax deductions in excess of compensation costs (excess tax benefits) are recorded in equity and tax deduction shortfalls (tax deficiencies), to the extent of previous excess tax benefits, are recorded in equity and then to income tax expense. Under the new guidance, all excess tax benefits and tax deficiencies will be recorded to income tax expense in the income statement, which could create volatility in the Company's income statement. The new guidance will also change the classification of excess tax benefits in the cash flow statement and impact the diluted earnings per share calculation. The guidance will be effective for interim and annual periods beginning after December 15, 2016, and early adoption is permitted. Different components of the guidance require prospective, retrospective and/or modified retrospective adoption. The Company does not expect that this standard will have a significant impact on its consolidated financial statements and disclosures upon adoption.

In February 2016, the FASB issued ASU 2016-02, Leases, This statement requires lessees to present right-of-use assets and lease liabilities on the balance sheet. The standard is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the effect the guidance will have on its financial condition and results of operations.

In November 2015, the FASB issued ASU 2015-17, Income Taxes, Balance Sheet Classification of Deferred Taxes topic of the Codification. This standard requires all deferred tax assets and liabilities to be classified as non-current on the balance sheet instead of separating deferred taxes into current and non-current amounts. In addition, valuation allowance allocations between current and non-current deferred tax assets are no longer required because those allowances also will be classified as non-current. This standard is effective for public companies for annual periods beginning after December 15, 2016. The Company's deferred tax assets are provided with full valuation allowance as of December 31, 2016 and 2015, except the deferred tax liability related to goodwill amortization. As such, the Company does not expect that this standard will have a significant impact on its consolidated financial statements and disclosures upon adoption.

In July 2015, The FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11"). ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company does not expect that this standard will have a significant impact on its consolidated financial statements and disclosures upon adoption.

In May 2014, The FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"). ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures. For a public entity, the amendments in ASU 2014-09 were to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB voted for a one year deferral of the effective date of ASU 2014-09 and issued an exposure draft. The new guidance will be effective for annual and interim periods beginning on or after December 15, 2017. Early application is not permitted. The Company is evaluating this standard and expect to have its analysis completed by mid-2017, however, preliminarily the Company does not expect that this new guidance will have a material impact on its revenue recognition.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provides guidance on management's responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provides guidance related to the required disclosures as a result of management evaluation. The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of the new guidance will not impact the Company's results of operations, cash flows or financial condition.

Acquisition

12 Months Ended

Dec. 31, 2016

Acquisition [Abstract]

Acquisition

Note 2

Acquisition:

On June 22, 2015, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with PhotoMedex Inc. and PhotoMedex Technology, Inc. pursuant to which the Company has purchased the XTRAC and VTRAC laser businesses from PhotoMedex, Inc. (the "Asset Purchase") for $42,528 in cash and assumed certain business-related liabilities. In June 2016, the Company received a return from the escrow account of $125 of the purchase price related to the assets in the purchased Indian subsidiary. The purchased assets include all of the accounts receivable, inventory and fixed and intangible assets of the business.

The fair value of the assets acquired and liabilities assumed were based on management estimates. The significant intangible assets to be recognized in the valuation are core and product technologies, tradenames and customer relationships. The estimated useful lives over which these assets will be amortized, utilizing the straight line method, are five years for product technologies and ten years for core technologies, tradenames and customer relationships. The Company estimated fair value of the intangibles and lasers placed in service was based on the income approach which estimated cash flow that utilize appropriate discount and capitalization rates and available market information. Estimates of future cash flows are based on a number of factors including the historical operating results, known trends and specific market and economic conditions. The fair value of the Company's remaining fixed assets was estimated based on the cost approach which estimated the cost to replace.

Current assets	$	7,233
Property, plant and equipment		14,340
Identifiable intangible assets		16,100
Other assets		45
Total assets assumed		37,718

Current liabilities		(3,945	)
Note payable		(57	)
Other long term liabilities		(116	)
Total liabilities assumed		(4,118	)

Net assets acquired	$	33,600

The purchase price exceeded the fair value of the net assets acquired by $8,803, which was recorded as goodwill.

The consolidated results of operations do not include any revenues or expenses related to XTRAC and VTRAC businesses on or prior to June 22, 2015, the date of the asset purchase. The Company's unaudited pro-forma results for the year ended December 31, 2015 summarize the combined results in the following table, assuming the asset purchase had occurred on January 1, 2015 and after giving effect to the acquisition adjustments, including amortization of the tangible and long-lived intangible assets acquired in the transaction:

	Year Ended December 31, 2015
	(unaudited)

Net revenues	$	33,163
Net loss attributable to common shareholders	$	(34,252	)
Net loss per basic and diluted share:	$	(4.01	)
Shares used in calculating net loss per basic and diluted share:		8,536,699

These unaudited pro-forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations which would have actually resulted had the acquisition occurred on January 1, 2015, nor to be indicative of future results of operations.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Inventories

12 Months Ended

Dec. 31, 2016

Inventories [Abstract]

Inventories

Note 3

Inventories:

	December 31, 2016		December 31, 2015

Raw materials and work in progress	$	2,440	$	3,706
Finished goods		377		422
	$	2,817	$	4,128

Work-in-process is immaterial, given the Company's typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials. During the year ended December 30, 2015 the Company initiated plans to develop an updated version of the MelaFind system and, accordingly, determined that a majority of its existing inventory of MelaFind systems and related parts exceeded its requirements. As a result, the Company wrote-off the excess and obsolete MelaFind inventories of $5,688, including $870 previously reserved.

Property and Equipment, net

12 Months Ended

Dec. 31, 2016

Property and Equipment, net [Abstract]

Property and Equipment, net

Note 4

Property and Equipment, net:

	December 31, 2016			December 31, 2015

Lasers placed-in-service	$	16,712		$	15,782
Equipment, computer hardware and software		160			1,219
Furniture and fixtures		111			2,080
Leasehold improvements		25			931
		17,008			20,012
Accumulated depreciation and amortization		(6,828	)		(6,161	)
Property and equipment, net	$	10,180		$	13,851

Depreciation and related amortization expense was $4,551 and $3,141 for the year ended December 31, 2016 and 2015, respectively. During the second quarter of 2015, the Company evaluated the future cash flows of the MelaFind devices with remaining net book value, determined there was an impairment and recorded an impairment charge of $920. During the year ended December 31, 2016, the Company disposed of leasehold improvements, machinery and equipment and furniture and fixtures with a recorded cost of $3,933 and accumulated depreciation and amortization of $3,809, related to the closing of its Irvington, New York facility. The net book value of $124 was written off to general and administrative expense.

Other Intangible Assets

12 Months Ended

Dec. 31, 2016

Other Intangible Assets [Abstract]

Other Intangible Assets

Note 7

Other Intangible Assets:

Set forth below is a detailed listing of other definite-lived intangible assets:

	December 31, 2016			December 31, 2015

Customer relationships	$	6,900		$	6,900
Tradenames		1,500			1,500
		8,400			8,400
Accumulated amortization		(1,260	)		(420	)
Other intangible assets, net	$	7,140		$	7,980

Related amortization expense was $840 and $420 for the years ended December 31, 2016 and 2015, respectively. Customer Relationships embody the value to the Company of relationships that PhotoMedex, for the XTRAC and VTRAC products, had formed with its customers. Trademarks include the tradenames and various trademarks associated with the products (e.g. "XTRAC" and "VTRAC"). Amortization of these intangibles is on a straight-line basis over 10 years for each of the customer relationships and tradenames.

Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:

2017	$	840
2018		840
2019		840
2020		840
2021		840
Thereafter		2,940
Total	$	7,140

Convertible Debentures

12 Months Ended

Dec. 31, 2016

Convertible Debentures [Abstract]

Convertible Debentures

Note 9

Convertible Debentures:

In the following table is a summary of the Company's convertible debentures.

	December 31, 2016		December 31, 2015

Senior secured 2.25% convertible debentures, net of unamortized debt discount of $24,314 and $26,267, respectively; and deferred financing costs of $524 and $522, respectively	$	7,174	$	5,489
Senior secured 4% convertible debentures, net of unamortized debt discount of $3,469 and $3,922, respectively; and deferred financing costs of $392 and $443, respectively		4,854		4,350
Total convertible debt	$	12,028	$	9,839

The Company issued $32,500 aggregate principal amount of Debentures (June 2015 Debentures) that, subject to certain ownership limitations and stockholder approval conditions, will be convertible into 43,333,334 shares of Company common stock at an initial conversion price of $0.75 per share. The Debentures bear interest at the rate of 2.25% per year, and, unless previously converted, will mature on the five-year anniversary of the date of issuance, June 22, 2020. If the Company cannot maintain its listing on Nasdaq, it would be deemed a default under the 2015 debentures.

The June 2015 Debentures include a beneficial conversion feature valued at $27,300 that was recorded as a discount to the debentures. On the date of issuance the beneficial conversion feature value was calculated as the difference resulting from subtracting the conversion price of $0.75 from $1.38, the opening market value of the Company's common stock following the announcement of the transaction, multiplied by the number of common shares into which the June 2015 Debentures are convertible. This discount is being amortized over the five year life of the June 2015 Debentures using the effective interest method. The embedded conversion feature contains an anti-dilution provision that allows for downward exercise price adjustments in certain situations. The embedded conversion feature was not bifurcated as it did not meet all of the elements of a derivative.

On July 21, 2014, the Company entered into a definitive Securities Purchase Agreement (the "Purchase Agreement") with institutional investors (the "Investors") providing for the issuance of Senior Secured Convertible Debentures in the aggregate principal amount of $15,000, due, subject to the terms therein, in July 2019 (the "July 2014 Debentures"), and warrants (the "July 2014 Series A Warrants") to purchase up to an aggregate of 6,198,832 shares of common stock, $0.001 par value per share, at an exercise price of $2.45 per share expiring in July 2019. The July 2014 Debentures bear interest at an annual rate of 4%, payable quarterly or upon conversion into shares of common stock. The Debentures are convertible at any time into an aggregate of 5,847,955 shares of common stock at an initial conversion price of $2.565 per share. The Company's obligations under the July 2014 Debentures are secured by a first priority lien on all of the Company's intellectual property pursuant to the terms of a security agreement ("Security Agreement") dated July 21, 2014 among the Company and the Investors. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with the Investors pursuant to which the Company was obligated to file a registration statement to register for resale the shares of Common Stock issuable upon conversion of the Series B Preferred Stock (See Note 12, Warrants) and Debentures and upon exercise of the Warrants. Proceeds from the Debentures were used for general working capital purposes.

For financial reporting purposes, the $15,000 funded by the Investors on July 21, 2014 was allocated first to the fair value of the obligation to issue the Warrants, amounting to $5,296, then to the intrinsic value of the beneficial conversion feature on the July 2014 Debentures of $4,565. The balance was further reduced by the fair value of warrants issued to the placement agent for services rendered of $491, resulting in an initial carrying value of the Debentures of $4,647. The initial debt discount on the July 2014 Debentures totaled $10,353 and is being amortized using the effective interest method over the five year life of the July 2014 Debentures.

During the year ended December 31, 2016, the investors converted June 2015 debentures amounting to $265 into 354,411 shares of common stock. The debt discount and deferred financing cost adjustment resulting from the conversions increased interest expense by $217 for the year ended December 31, 2016.

As a condition of the new note facility (See Note 10, Long-term Debt below) the Debentures from both the 2014 and 2015 financings were amended. The Debentures holders' first priority lien was subordinated to the new term note facility. Additionally, as a condition of the term note facility, the maturity date of both Debentures was extended to June 30, 2021. The Company evaluated the modifications to determine if there was an extinguishment of debt. Based on the valuation, the discounted cash flows did not change by more than 10%, thus they were treated as a modification.

As of December 31, 2016, the total outstanding amount of Debentures was $40,727.

Long-term Debt

12 Months Ended

Dec. 31, 2016

Long-term Debt [Abstract]

Long-term Debt

Note 10

Long-term Debt:

	December 31,
	2016			2015

Term note, net of debt discount of $258 and $287, respectively; and deferred financing cost of $276 and $306, respectively	$	11,466		$	9,851
Less: current portion		(1,714	)		-
Total long-term debt	$	9,752		$	9,851

Term-Note Credit Facility

On December 30, 2015, the Company entered into a $12,000 credit facility pursuant to a Credit and Security Agreement (the "Agreement") and related financing documents with MidCap Financial Trust ("MidCap") and the lenders listed therein. Under the Agreement, the credit facility may be drawn down in two tranches, the first of which was drawn for $10,500 on December 30, 2015. The proceeds of this first tranche were used to repay $10,000 principal amount of short-term senior secured promissory notes, plus associated interest, loan fees and expenses. The second tranche was drawn for $1,500 on January 29, 2016. On August 8, 2016, the minimum net revenue covenant was amended prospectively. The Company was in compliance with these covenants as of December 31, 2016. The payment term of the credit facility is 60 months, with first 18 months as interest only. The Interest rate on the credit facility is one month LIBOR plus 8.25%, subject to a LIBOR floor of 0.5%. The Company's existing debentures from its 2014 and 2015 financings were amended as a condition of this new term note facility, including subordination agreements and maturity extensions. Additionally if the Company cannot maintain its listing on Nasdaq, it would be deemed a default under the 2015 debentures and a breach of our affirmative covenants and therefore an event of default under the financing documents with Midcap. Unamortized discount on the long term debt and deferred financing costs was $534 and $649 as of December 31, 2016 and 2015, respectively. As of December 31, 2016 the net balance of long-term debt is $11,466.

The following table summarizes the future payments that the Company expects to make for long-term debt:

2017	$	1,714
2018		3,429
2019		3,429
2020		3,428
		12,000

In connection with the issuance of the Term Note the Company issued MidCap (and the lenders), on December 30, 2015, a warrant to purchase 650,442 shares of the Company's common stock for an exercise price of $1.13. Additionally, the Company issued MidCap (and the lenders), on January 29, 2016, a warrant to purchase 99,057 shares of the Company's common stock for an exercise price of $1.06. The warrants are exercisable at any time on or prior to the fifth anniversary of its issue date. The warrants are treated as a discount to the debt and that discount is accreted under the effective interest method over the repayment term of 60 months. The Company has accounted for these warrants as equity instruments since there is no option for cash or net-cash settlement when the warrants are exercised and since they are indexed to the Company's common stock. The Company computed the value of the warrants using the Black-Scholes method.

The key assumptions used to value the warrants are as follows:

	December 31, 2015			January 29, 2016

Number of shares underlying warrants		650,442			99,057
Exercise price	$	1.13		$	1.06
Stock price on date of issuance	$	1.11		$	1.05
Fair value of warrants	$	321		$	47
Volatility		50.0	%		50.0	%
Risk-free interest rate		1.8	%		1.8	%
Expected dividend yield		0	%		0	%
Expected warrant life	5 years			5 years

Commitments and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 11

Commitments and Contingencies:

Leases

The Company has entered into various non-cancelable operating lease agreements for real property and three minor operating leases for personal property. These arrangements expire at various dates through 2018. Rent expense was $783 and $748 for the years ended December 31, 2016 and 2015, respectively.

The future annual minimum payments under these leases, relating to our continuing operations are as follows:

Year Ending December 31,
2017	$	432
2018		220
Total	$	652

Warrants

12 Months Ended

Dec. 31, 2016

Warrants [Abstract]

Warrants

Note 12

Warrants:

The Company accounts for warrants that have provisions that protect holders from a decline in the issue price of its common stock (or "down-round" provisions) and those that contain cash settlement provisions as liabilities instead of equity. Down-round provisions reduce the exercise or conversion price of a warrant or convertible instrument if a company either issues equity shares for a price that is lower than the exercise or conversion price of those instruments or issues new warrants or convertible instruments that have a lower exercise or conversion price. Net settlement provisions allow the holder of the warrant to surrender shares underlying the warrant equal to the exercise price as payment of its exercise price, instead of physically exercising the warrant by paying cash. The Company evaluated whether warrants to acquire its common stock contain provisions that protect holders from declines in the stock price or otherwise could result in modification of the exercise price and/or shares to be issued under the respective warrant agreements based on a variable that is not an input to the fair value of a "fixed-for-fixed" option. As of June 22, 2016, the down-round provision expired on 12,083,821 warrants and as such $1,541 of value associated with these warrants was reclassified to equity.

For those that do contain such provisions, the Company recognizes such warrants as liabilities at the fair value on each reporting date. The Company measured the fair value of these warrants as of December 31, 2015, and recorded other income of $1,814 resulting from the decrease of the liability associated with the fair value of the warrants for the year ended December 31, 2015. The Company computed the value of the warrants using the binomial method. A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2016, June 22, 2016 and December 31, 2015 is as follows:

	December 30, 2016			June 22, 2016			December 31, 2015

Number of shares underlying the warrants		2,015,446			12,083,821			14,099,267
Stock price	$	0.44		$	0.65		$	1.11
Volatility		47.00	%		35.00 - 50.00	%		35.90 – 50.00	%
Risk-free interest rate		1.22	%		0.25% – 1.04	%		0.02% - 1.63	%
Expected dividend yield		0	%		0	%		0	%
Expected warrant life	2.12 – 2.35 years			0.09– 4.0 years			0.07 – 4.48 years

Recurring Level 3 Activity and Reconciliation

The table below provides a reconciliation of the beginning and ending balances for the liability measured at fair value using significant unobservable inputs (Level 3). The table reflects gains and losses for the years ended December 31, 2016 and 2015, for all financial liabilities categorized as Level 3 as of December 31, 2016 and 2015, respectively.

Fair Value Measurements Using Significant Unobservable Inputs (Level 3):

Issuance Date	December 31, 2015		Decrease in Fair Value			Reclassification to Equity			December 31, 2016

10/31/2013	$	379	$	(340	)	$	-		$	39
2/5/2014		715		(649	)		-			66
7/24/2014 Series A		2,415		(1,573	)		(842	)		-
7/24/2014 Series B		1,726		(1,713	)		(13	)		-
6/22/2015		1,807		(1,121	)		(686	)		-

Total	$	7,042	$	(5,396	)	$	(1,541	)	$	105

Issuance Date	January 1, 2015		Initial Measurements		Reclassed from Equity		Increase (Decrease) in Fair Value			December 31, 2015

10/31/2013	$	233	$	-	$	-	$	146		$	379
2/5/2014		266		-		-		449			715
7/24/2014 Series A		-		-		3,452		(1,037	)		2,415
7/24/2014 Series B		-		-		1,947		(221	)		1,726
6/22/2015		-		2,958		-		(1,151	)		1,807

Total	$	499	$	2,958	$	5,399	$	(1,814	)	$	7,042

Number of Warrants Subject to Remeasurement:

Issuance Date	December 31, 2015	Reductions	December 31, 2016

10/31/2013	685,715	-	685,715
2/5/2014	1,329,731	-	1,329,731
7/24/2014 Series A	4,288,500	(4,288,500)	-
7/24/2014 Series B	4,795,321	(4,795,321)	-
6/22/2015	3,000,000	(3,000,000)	-

Total	14,099,267	(12,083,821)	2,015,446

Stockholders' Equity

12 Months Ended

Dec. 31, 2016

Stockholders' Equity [Abstract]

Stockholders' Equity

Note 13

Stockholders' Equity:

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company's Board of Directors. There were 6,000 shares and 6,505 shares of Series B convertible preferred stock issued and outstanding on December 31, 2016 and 2015, respectively.

On February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold an aggregate of 12,300 shares of Series A convertible preferred stock, par value $0.10 and a stated value of $1,000 per share convertible into 1,464,287 shares of common stock at an initial conversion price of $8.40, and warrants to purchase up to 1,329,731 shares of common stock for net proceeds of $11,458. The warrants have an exercise price of $7.40 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014 and at each subsequent balance sheet date.

In connection with this financing, the Company also granted resale registration rights with respect to the shares of common stock underlying the Series A preferred stock and the warrants pursuant to the terms of a Registration Rights Agreement. The purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of $3,420 during the year ended December 31, 2014. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014.

On July 24, 2014, in connection with the July 2014 Debentures (see Note 9, Convertible Debentures), the Company exchanged 12,300 shares of Series A convertible preferred stock issued on February 5, 2014 with 12,300 shares of Series B convertible preferred stock at a stated value of $1,000 per share convertible into common stock at an initial price of $2.565 per share. The preferred stock is immediately convertible into an aggregate of 4,795,321 shares of common stock. Holders of the Series B convertible preferred stock are entitled to dividends only in the event that dividends are paid on the common stock, and the preferred stock has no preferences over the common stock. In connection with the exchange, the Company issued the July 2014 Series B warrants to purchase up to an aggregate of 4,795,321 shares of common stock at an exercise price of $2.45 per share, expiring in January 2016. The July 2014 Series B warrants are immediately exercisable and are subject to certain ownership limitations.

The $12,300 preferred stock value was allocated first to the fair value of the July 2014 Series B warrants, which totaled $2,487, then to the intrinsic value of the beneficial conversion feature of $1,887. The amount of the beneficial conversion feature was considered to be a deemed dividend on the date of issuance to the Series B preferred stockholders. Pursuant to the terms of the Purchase Agreement, the Series A convertible preferred stock was redeemed from the proceeds of the Series B convertible preferred stock. In September 2014, the Company amended the registration statement related to the Series A preferred stock to deregister those shares that would have been issuable upon conversion of the Series A preferred stock had it not already been redeemed by the proceeds of the Series B preferred stock.

During year ending December 31, 2016, 504.5 shares of Series B preferred stock were converted into 196,686 shares of common stock.

Common Stock and Warrants

The Company is authorized to issue 150,000,000 shares of common stock with a par value of $0.001 per share. There were 10,834,490 and 10,283,393 issued and outstanding at December 31, 2016 and 2015, respectively.

On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6,000,000 registered offering of 422,819 shares of the Company's common stock, fully paid prefunded warrants (the "October 2013 Series B Warrants") to purchase up to 434,325 shares of its common stock and additional warrants ("October 2013 Series A Warrants") to purchase up to 685,715 shares of its common stock. The October 2013 Series A Warrants are exercisable beginning on May 1, 2014 at a price of $8.50 per share and expire on May 1, 2019. The October 2013 Series B Warrants were exercisable immediately for no additional consideration. The offering closed on October 31, 2013. The holders exercised all of the October 2013 Series B Warrants in March 2014.

The October 2013 Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date.

Outstanding common stock warrants consist of the following:

Issue Date	Expiration Date	Total Warrants		Exercise Price

4/26/2013	4/26/2018		69,321	$	11.18
10/31/2013	4/30/2019		685,715	$	0.75
2/5/2014	2/5/2019		1,329,731	$	0.75
7/24/2014	7/24/2019		6,198,832	$	0.75 - $ 2.45
6/22/2015	6/22/2020		3,000,000	$	0.75
12/30/2015	12/30/2020		650,442	$	1.13
1/29/2016	1/29/2021		99,057	$	1.06
			12,033,098

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Stock-based compensation

12 Months Ended

Dec. 31, 2016

Stock-based compensation [Abstract]

Stock-based compensation

Note 14

Stock-based compensation:

Stock Options

On October 27, 2016, the Company's stockholders approved the Company's adoption of the new 2016 Omnibus Incentive Stock Plan ("2016 Plan") having 10,294,400 shares available for issuance in respect of awards made thereunder. The Company terminated the 2013 Stock Incentive Plan in October 2016. As of December 31, 2016, the aggregate number of shares of common stock remaining available for issuance for awards under the 2016 Plan totaled 8,294,400.

A summary of option transactions for all of the Company's stock options during the years ended December 31, 2016 and 2015 follows:

	Number of Stock Options			Weighted Average Exercise Price
Outstanding at December 31, 2014		1,308,835		$	2.76
Granted		1,487,500			1.15
Exercised		-			-
Expired/cancelled		(111,983	)		10.70
Outstanding at December 31, 2015		2,684,352			1.54
Granted		2,340,000			0.58
Exercised		-			-
Expired/cancelled		(523,830	)		2.07
Outstanding at December 31, 2016		4,500,522		$	1.02
Exercisable at December 31, 2016		2,200,672		$	1.48
Options expected to vest at December 31, 2016		2,049,850		$	0.59

The outstanding and exercisable options at December 31, 2016, have a range of exercise prices and associated weighted remaining contractual life and weighted average exercise price, as follows:

Options Range of Exercise Prices		Outstanding Number of Shares		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Exercisable Number of Shares		Exercisable Weighted Avg. Exercise Price
$	0 - $1.25		3,827,500		9.41	$	0.80		1,530,000	$	1.14
$	1.26 - $5.00		625,000		7.93		1.58		625,000		1.58
$	5.01 - $10.00		36,022		6.78		7.06		34,597		7.08
$	10.01 - $63.00		12,000		5.60		24.19		11,075		24.27
Total			4,500,522		9.17	$	1.02		2,200,672	$	1.48

As the share price as of December 31, 2016 was $0.44, the aggregate intrinsic value for options outstanding and exercisable was immaterial.

Stock awards under the Company's stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant.

The fair value of each option award granted during the period is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

	Years Ended December 31,
	2016	2015
Risk-free interest rate	1.51 – 2.18%	1.80 - 1.90%
Volatility	50.00%	50.00 - 85.68%
Expected dividend yield	0%	0%
Expected life	6.5 years	6.5 years
Estimated forfeiture rate	0%	0%

The expected life of the options is based on the observed and expected time to full-vesting, forfeiture and exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. The risk-free rate is based on rates provided by the U.S. Treasury with a term equal to the expected life of the option. The Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

During December 2015 the Company changed its method of calculating expected volatility that is used in its fair value measurements and measurements of share based compensation cost. The new method estimates expected volatility by using a combination of the Company's historical volatility since June 22, 2015, the acquisition date of the XTRAC and VTRAC businesses, plus the historical volatility of stocks of similar publicly-traded companies for a period matching the expected term of the underlying instrument. The Company believes that this method provides for a better estimate of future volatility because of the significant change to the overall Company resulting from the acquisition of the XTRAC and VTRAC businesses on June 22, 2015. The Company had historically calculated expected volatility based solely upon the historical volatility of the Company's daily closing stock price.

On December 6, 2016, the Company granted an aggregate of 450,000 options to purchase common stock to the non-employee board directors with a strike price of $0.55. The options vest over a one year period and expire ten years from the date of grant. The aggregate fair value of the options granted was $182.

On October 31, 2016, the Company issued 542,500 options to purchase common stock to its' Chief Executive Officer with a strike price of $0.55. The options vest over three years and expire ten years from the date of grant. The aggregate fair value of the options granted was $150. Additionally, the Company issued 1,007,500 options to purchase common stock to its' Chief Executive Officer with a strike price of $0.55. These options vest based on performance goals determined by the board of directors for each of the years 2017 through 2019.

On June 7, 2016, the Company granted an aggregate of 340,000 options to purchase common stock to a number of employees with a strike price of $0.75. The options vest over four years and expire ten years from the date of grant. The aggregate fair value of the options granted was $128.

Stock-based compensation expense, primarily included in general and administration, for the years ended December 31, 2016 and 2015 was $113 and $1,753, respectively. As of December 31, 2016 there was $371 in unrecognized compensation expense, which will be recognized over a weighted average period of 1.3 years.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2016

Income taxes [Abstract]

Income Taxes

Note 15

Income Taxes:

	Year Ended December 31,
	2016			2015
Current:
Federal	$	-		$	-
State		15			-
		15			-
Deferred
Federal		(4,119	)		3,302
State		(648	)		388
		(4,767	)		3,690
Valuation allowance		5,007			(3,571	)
Income tax expense	$	255		$	119

The Company accounts for income taxes using the asset and liability method for deferred income taxes.

The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.

The Company provides for income taxes offset by changes in valuation allowances.

The difference between the actual income tax benefit and that computed by applying the U.S. federal income tax rate of 34% to pretax loss from continuing operations is summarized below:

	For the Years Ended December 31,
	2016			2015

Computed expected tax benefit	$	(1,047	)	$	(8,472	)
State tax benefit, net of federal effect		(499	)		(1,365	)
Warrant value fluctuation		(1,835	)		3,271
Net increase in valuation allowance		3,636			6,685
Provision for income taxes	$	255		$	119

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2016 and 2015 are as follows:

	December 31,
	2016			2015

Deferred tax assets/(liabilities):
Net operating loss carryforward	$	72,870		$	64,075
Capitalized research and developmental costs		8,711			10,543
Inventory		149			47
Reserves & accrued expenses		291			3,295
Convertible debt discount		(11,097	)		(11,182	)
Property & equipment		432			(355	)
Non-cash compensation		1,127			1,054
Goodwill		(359	)		(119	)
Total deferred tax assets		72,124			67,358
Less: valuation allowance		(72,483	)		(67,477	)
Net deferred tax assets/(liabilities)	$	(359	)	$	(119	)

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based on the Company's historical net losses, management does not believe that it is more-likely-than not that the Company will realize the benefits of these deferred tax assets and, accordingly, a full valuation allowance has been recorded against the deferred tax assets as of December 31, 2016 and 2015. The Company's valuation allowance against its deferred tax assets increased by $5,035 for the year ended December 31, 2016 and decreased by $3,571 for the year ended December 31, 2015.

At December 31, 2016 and 2015, the Company has federal net operating loss carryforwards of approximately $183,727 and $163,837, respectively, to offset future taxable income. The Company has experienced certain ownership changes which, under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, result in annual limitations on the Company's ability to utilize its net operating losses in the future. The February 2014, July 2014 and June 2015 equity raises by the Company, will likely limit the annual use of these net operating loss carryforwards.

FASB ASC 740 "Income Taxes" contains guidance with respect to uncertain tax positions which applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to recognize. Tax positions that meet the more likely than not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority.

The Company does not have any unrecognized tax benefits or accrued penalties and interest. If such matters were to arise, the Company would recognize interest and penalties related to income tax matters in income tax expense. The earliest open tax year subject to examination is 2011.

Business Segments and Geographic Data

12 Months Ended

Dec. 31, 2016

Business Segments and Geographic Data [Abstract]

Business Segments and Geographic Data

Note 16

Business Segments and Geographic Data:

The Company organized its business into three operating segments to better align its organization based upon the Company's management structure, products and services offered, markets served and types of customers, as follows: The Dermatology Recurring Procedures segment derives its revenues from the XTRAC procedures performed by dermatologists. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The Dermatology Imaging segment generates revenues from the sale and usage of imaging devices. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance. On June 22, 2015, the Company acquired the XTRAC and VTRAC businesses and has classified the revenues and expenses of this business to the two Dermatology Procedures segments. Accordingly, these revenues and operating expenses are included only for the period of June 23, 2015 through December 31, 2016.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense), net is also not allocated to the operating segments.

The following tables reflect results of operations from our business segments for the periods indicated below:

Year Ended December 31, 2016

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	24,558		$	7,065		$	134		$	31,757
Costs of revenues		8,763			3,506			367			12,636
Gross profit		15,795			3,559			(233	)		19,121
Gross profit %		64.3	%		50.4	%		(173.9	%)		60.2	%

Allocated operating expenses:
Engineering and product development		1,288			210			431			1,929
Selling and marketing expenses		12,591			375			186			13,152

Unallocated operating expenses		-			-			-			7,637
		13,879			585			617			22,718
Income (loss) from operations		1,916			2,974			(850	)		(3,597	)

Interest expense, net		-			-			-			(4,900	)
Change in fair value of warrant liability		-			-			-			5,396
Other income (expense), net		-			-			-			21

Income (loss) before income taxes	$	1,916		$	2,974		$	(850	)	$	(3,080	)

Year Ended December 31, 2015

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	14,616		$	3,591		$	288		$	18,495
Costs of revenues		4,680			1,989			7,050			13,719
Gross profit		9,936			1,602			(6,762	)		4,776
Gross profit %		68.0	%		44.6	%		(2347.8	%)		25.8	%

Allocated operating expenses:
Engineering and product development		676			104			1,249			2,029
Selling and marketing expenses		7,128			193			1,873			9,194

Unallocated operating expenses		-			-			-			10,028
		7,804			297			3,122			21,251
Income (loss) from operations		2,132			1,305			(9,884	)		(16,475	)

Interest expense, net		-			-			-			(10,200	)
Change in fair value of warrant liability		-			-			-			1,814
Other income (expense), net		-			-			-			33

Income (loss) before income taxes	$	2,132		$	1,305		$	(9,884	)	$	(24,828	)

For the year ended December 31, 2016 and 2015 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows:

	Years Ended December 31,
	2016		2015
Domestic	$	25,536	$	14,724
Foreign		6,221		3,771
	$	31,757	$	18,495

As of December 31, 2016 and 2015, total assets by reportable segment were as follows:

	December 31,
Assets:	2016		2015
Dermatology Recurring Procedures	$	34,612	$	40,420
Dermatology Procedures Equipment		3,980		5,364
Dermatology Imaging		265		661
Other unallocated assets		4,336		3,634
Consolidated total	$	43,193	$	50,079

Long lived assets were 100% located in domestic markets for both of the years ended December 31, 2016 and 2015.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Related Parties	12 Months Ended
Related Parties	Dec. 31, 2016
Related Parties [Abstract]
Related Parties	Note 17 Related Parties: On June 22, 2015, the Company entered into a securities purchase agreement with the Purchasers, including certain funds managed by Sabby Management, LLC and Broadfin Capital LLC (existing Company shareholders), in connection with a private placement. We sold $10.0 million aggregate principal amount of Notes bearing interest at 9% per year, with a maturity date of the earlier of 30 days after the Company obtains stockholder approval of stock issuances under the Debentures and the Warrants or November 30, 2015. The Purchasers of the Notes were issued Warrants to purchase an aggregate of 3.0 million shares of common stock, having an exercise price of $0.75 per share. We also issued $32.5 million aggregate principal amount of Debentures that, subject to certain ownership limitations and stockholder approval conditions, will be convertible into 43,333,334 shares of common stock at an initial conversion price of $0.75 per share. The Debentures bear interest at the rate of 2.25% per year, and, unless previously converted, will mature on the five-year anniversary of the date of issuance. Our obligations under the Debt Securities are secured by a first priority lien on all of our assets, except for a second lien on our intellectual property. As a condition of the new term note facility (See Note 10, Long-term Debt) the Debentures from both the 2014 and 2015 financings were amended. The Debentures holders' first priority lien was subordinated to the new term note facility. Additionally, as a condition of the term note facility, the maturity date of both Debentures was extended to June 30, 2021. Effective upon the date the Stockholder Approval, on September 30, 2015, the Company repriced outstanding Warrants held by certain investors to reduce the exercise price to $0.75 per share. In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Debentures and the Warrants pursuant to the terms of the Registration Rights Agreement. In addition to the registration rights, the Selling Stockholders are entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, becoming effective and maintaining an effective registration statement covering the shares underlying the Debentures and the Warrants. The liquidated damages will be payable upon the occurrence of each of those events and each monthly anniversary thereof until cured. The amount of liquidated damages payable is equal to 2.0% of the aggregate purchase price paid by each Purchaser, provided, however, the maximum aggregate liquidated damages payable to a Purchaser shall be 12% of the aggregate subscription amount paid by such Purchaser pursuant to the Purchase Agreement. The liquidated damages shall accrue interest at a rate of 12% per annum (or such lesser maximum amount that is permitted to be paid by applicable law), accruing on a daily basis for each event until such event is cured. The Registration Rights Agreement requires the Company to file one or more registration statements for all of the securities that may be issued upon conversion of the Debentures and exercise of the Warrants issued to the Purchasers. Pursuant to the applicable transaction documents, however, certain Purchasers may not exercise their conversion/exercise rights for that number of shares of common stock which, together with all other shares owned by that Purchaser and its affiliates would result in more than 9.99% of our issued and outstanding shares of common stock calculated on the basis of the then outstanding shares. On November 4, 2015, the Company entered into consulting agreements with two of its directors, Jeffrey F. O'Donnell, Sr. and Samuel E. Navarro, the terms of which are the same. Under the terms of their respective agreements, each director agrees to provide strategic support, advice and guidance to the Company and its management team in connection with the integration and operation of the expanded business, investor relations and internal and external business development activities. The consultant will make himself available to the Company's President and Chief Executive Officer and the management team on request at mutually convenient times and will report to the Board of Directors quarterly and otherwise when requested by the Board. The initial term of the agreement was from November 4, 2015 through June 30, 2016. The agreements have been extended through June 30, 2017. The directors are each to be paid an up-front fee of $40,000 for advice and services rendered prior to the date of the agreement, a retainer of $10,000 per month, commencing November 10, 2015 and continuing on the tenth day of each month through June 10, 2016, and reimbursement of pre-approved, out-of-pocket expenses.

Significant Customer Concentration	12 Months Ended
Significant Customer Concentration	Dec. 31, 2016
Significant Customer Concentration [Abstract]
Significant Customer Concentration	Note 18 Significant Customer Concentration: For the year ended December 31, 2016, revenues from sales to the Company's international master distributor (GlobalMed Technologies) were $6,093, or 19.2%, of total revenues for such period. At December 31, 2016, the accounts receivable balance from GlobalMed Technologies was $585, or 17.2%, of total net accounts receivable. For the year ended December 31, 2015, revenues from sales to the Company's international master distributor were $3,085, or 16.7%, of total revenues for such period. No other customer represented more than 10% of total company revenues for the year ended December 31, 2016 and 2015. No other customer represented more than 10% of total accounts receivable as of December 31, 2016.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 19 Subsequent Events: Convertible Debentures On January 12, 2017, investors converted debentures amounting to $19 into 25,000 shares of common stock. On January 27, 2017, investors converted debentures amounting to $19 into 25,000 shares of common stock. Additionally, on February 23, 2017, investors converted debentures amounting to $19 into 25,000 shares of common stock. See Note 9, Convertible Debentures. Other In March 2017, we sent a notice to the 90 owners of MelaFind devices informing them that, effective September 30, 2017, we no longer had the resources to continue to support the device and that our inventory of spare parts was being offered for sale to them on a first-come, first-serve basis. We can no longer manufacture parts for the device and we lack the resources to continue to develop the product.

The Company (Policies)

12 Months Ended

Dec. 31, 2016

The Company [Abstract]

Liquidity

Accounting Principles

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP").

Principles of Consolidation

Reclassification

Use of Estimates

Revenue Recognition

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property, Equipment and Depreciation

Patent Costs and Licensed Technologies

Other Intangible Assets

Accounting for the Impairment of Goodwill

Impairment of Long-Lived Assets and Intangibles

Functional Currency

Fair Value Measurements

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
	•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

The Company's recurring fair value measurements at December 31, 2016 and 2015 are as follows:

	Fair Value as of December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 12)	$	105	$	-	$	-	$	105


	Fair Value as of December 31, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 12)	$	7,042	$	-	$	-	$	7,042

Accrued Warranty Costs

	December 31,
	2016			2015

Accrual at beginning of year	$	226		$	48
Acquired in asset purchase		-			265
Additions charged to warranty expense		196			98
Expiring warranties/claimed satisfied		(307	)		(185	)
Total		115			226
Less: current portion		(102	)		(168	)
	$	13		$	58

Product Development Costs

Costs of research, new product development and product redesign are charged to expense as incurred in engineering and product development.

Advertising Costs

Advertising costs are charged to expenses as incurred. Advertising expenses amounted to approximately $4,389 and $2,500 for the years ended December 31, 2016 and 2015, respectively.

Income Taxes

Concentration of credit risks

Earnings Per Share

Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the year ended December 31, 2016:

	Year Ended December 31, 2016

Net loss	$	(3,335	)
Gain on the change in fair value of the warrant liability		(5,396	)
Diluted loss	$	(8,731	)

Weighted average number of common and common equivalent shares outstanding:
Basic number of common shares outstanding		10,595,068
Dilutive effect of warrants		983,505
Diluted number of common and common stock equivalent shares outstanding		11,578,573

For the year ended December 31, 2015, diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive.

		December 31,
	2016		2015
Common stock equivalents of convertible debentures	46,105,715		46,435,127
Common stock purchase warrants	12,033,098		16,729,362
Common stock equivalents of convertible preferred stock	2,339,180		2,535,866
Common stock options	4,503,522		2,684,352
Total	64,981,515		68,384,707

Stock-Based Compensation

Adoption of New Accounting Standards

Recently Issued Accounting Standards

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provides guidance on management's responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provides guidance related to the required disclosures as a result of management evaluation. The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of the new guidance will not impact the Company's results of operations, cash flows or financial condition.

The Company (Tables)

12 Months Ended

Dec. 31, 2016

The Company [Abstract]

Fair Value Measurements on Recurring Basis

The Company's recurring fair value measurements at December 31, 2016 and 2015 are as follows:

	Fair Value as of December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 12)	$	105	$	-	$	-	$	105


	Fair Value as of December 31, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 12)	$	7,042	$	-	$	-	$	7,042

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2016 and 2015 is summarized as follows:

	December 31,
	2016			2015

Accrual at beginning of year	$	226		$	48
Acquired in asset purchase		-			265
Additions charged to warranty expense		196			98
Expiring warranties/claimed satisfied		(307	)		(185	)
Total		115			226
Less: current portion		(102	)		(168	)
	$	13		$	58

Diluted Earnings Per Common Share Calculated Using Net Loss and Weighted Average Shares Outstanding

Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the year ended December 31, 2016:

	Year Ended December 31, 2016

Net loss	$	(3,335	)
Gain on the change in fair value of the warrant liability		(5,396	)
Diluted loss	$	(8,731	)

Weighted average number of common and common equivalent shares outstanding:
Basic number of common shares outstanding		10,595,068
Dilutive effect of warrants		983,505
Diluted number of common and common stock equivalent shares outstanding		11,578,573

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

		December 31,
	2016		2015
Common stock equivalents of convertible debentures	46,105,715		46,435,127
Common stock purchase warrants	12,033,098		16,729,362
Common stock equivalents of convertible preferred stock	2,339,180		2,535,866
Common stock options	4,503,522		2,684,352
Total	64,981,515		68,384,707

Acquisition (Tables)

12 Months Ended

Dec. 31, 2016

Acquisition [Abstract]

Estimated Fair Value of Assets Acquired and Liabilities Assumed

Current assets	$	7,233
Property, plant and equipment		14,340
Identifiable intangible assets		16,100
Other assets		45
Total assets assumed		37,718

Current liabilities		(3,945	)
Note payable		(57	)
Other long term liabilities		(116	)
Total liabilities assumed		(4,118	)

Net assets acquired	$	33,600

Unaudited Pro-forma Results

The Company's unaudited pro-forma results for the year ended December 31, 2015 summarize the combined results in the following table, assuming the asset purchase had occurred on January 1, 2015 and after giving effect to the acquisition adjustments, including amortization of the tangible and long-lived intangible assets acquired in the transaction:

	Year Ended December 31, 2015
	(unaudited)

Net revenues	$	33,163
Net loss attributable to common shareholders	$	(34,252	)
Net loss per basic and diluted share:	$	(4.01	)
Shares used in calculating net loss per basic and diluted share:		8,536,699

Inventories (Tables)

12 Months Ended

Dec. 31, 2016

Inventories [Abstract]

Schedule of Inventory

	December 31, 2016		December 31, 2015

Raw materials and work in progress	$	2,440	$	3,706
Finished goods		377		422
	$	2,817	$	4,128

Property and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2016

Property and Equipment, net [Abstract]

Summary of Property and Equipment, Net

	December 31, 2016			December 31, 2015

Lasers placed-in-service	$	16,712		$	15,782
Equipment, computer hardware and software		160			1,219
Furniture and fixtures		111			2,080
Leasehold improvements		25			931
		17,008			20,012
Accumulated depreciation and amortization		(6,828	)		(6,161	)
Property and equipment, net	$	10,180		$	13,851

Patents and Licensed Technologies, net (Tables)

12 Months Ended

Dec. 31, 2016

Patents and Licensed Technologies, net [Abstract]

Schedule of Patents and Licensed Technologies, Net

	December 31, 2016			December 31, 2015

Core technology	$	5,974		$	5,974

Product technology		2,000			2,000
		7,974			7,974
Accumulated amortization		(1,702	)		(727	)
Patents and licensed technologies, net	$	6,272		$	7,247

Estimated Amortization Expense for Amortizable Patents and Licensed Technologies Assets

Estimated amortization expense for amortizable patents and licensed technologies assets for the future periods is as follows:

2017	$	975
2018		975
2019		975
2020		775
2021		575
Thereafter		1,997
Total	$	6,272

Goodwill (Tables)

12 Months Ended

Dec. 31, 2016

Goodwill Disclosure [Abstract]

Schedule of Goodwill

Goodwill reflects the value or premium of the acquisition price in excess of the fair values assigned to specific tangible and intangible assets. Goodwill has an indefinite useful life and therefore is not amortized as an expense, but is reviewed annually for impairment based on its fair value to the Company. Goodwill was recorded on the acquisition of the XTRAC and VTRAC businesses as the purchase price exceeded the net assets of the business. (See Note 2, Acquisition.)

Balance at January 1, 2016	$	8,928
Return of purchase price from escrow		(125	)
Balance at December 31, 2016	$	8,803

The Company has no accumulated impairment losses of goodwill related to its continuing operations as of December 31, 2016.

The goodwill was allocated among the reportable segments as of December 31, 2016 in accordance with the provisions of ASC Topic 350-20 Intangibles-Goodwill and consisted of the following:

	December 31, 2016

Dermatology Recurring Procedures segment	$	7,958
Dermatology Procedures Equipment segment		845
Total goodwill	$	8,803

Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2016

Other Intangible Assets [Abstract]

Schedule of Other Definite-lived Intangible Assets

Set forth below is a detailed listing of other definite-lived intangible assets:

	December 31, 2016			December 31, 2015

Customer relationships	$	6,900		$	6,900
Tradenames		1,500			1,500
		8,400			8,400
Accumulated amortization		(1,260	)		(420	)
Other intangible assets, net	$	7,140		$	7,980

Finite-lived Intangible Assets Amortization Expense

Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:

2017	$	840
2018		840
2019		840
2020		840
2021		840
Thereafter		2,940
Total	$	7,140

Long-term Debt (Tables)

12 Months Ended

Dec. 31, 2016

Long-term Debt [Abstract]

Long-term Debt

	December 31,
	2016			2015

Term note, net of debt discount of $258 and $287, respectively; and deferred financing cost of $276 and $306, respectively	$	11,466		$	9,851
Less: current portion		(1,714	)		-
Total long-term debt	$	9,752		$	9,851

Summary of Maturities of Long-term Debt

The following table summarizes the future payments that the Company expects to make for long-term debt:

2017	$	1,714
2018		3,429
2019		3,429
2020		3,428
		12,000

Key Assumptions Used to Value the Warrants under Long-term Debt

The key assumptions used to value the warrants are as follows:

	December 31, 2015			January 29, 2016

Number of shares underlying warrants		650,442			99,057
Exercise price	$	1.13		$	1.06
Stock price on date of issuance	$	1.11		$	1.05
Fair value of warrants	$	321		$	47
Volatility		50.0	%		50.0	%
Risk-free interest rate		1.8	%		1.8	%
Expected dividend yield		0	%		0	%
Expected warrant life	5 years			5 years

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Warrants (Tables)

12 Months Ended

Dec. 31, 2016

Warrants [Abstract]

Warrants Fair Value Assumptions

A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2016, June 22, 2016 and December 31, 2015 is as follows:

	December 30, 2016			June 22, 2016			December 31, 2015

Number of shares underlying the warrants		2,015,446			12,083,821			14,099,267
Stock price	$	0.44		$	0.65		$	1.11
Volatility		47.00	%		35.00 - 50.00	%		35.90 – 50.00	%
Risk-free interest rate		1.22	%		0.25% – 1.04	%		0.02% - 1.63	%
Expected dividend yield		0	%		0	%		0	%
Expected warrant life	2.12 – 2.35 years			0.09– 4.0 years			0.07 – 4.48 years

Schedule of Fair Value Hierarchy

Fair Value Measurements Using Significant Unobservable Inputs (Level 3):

Issuance Date	December 31, 2015		Decrease in Fair Value			Reclassification to Equity			December 31, 2016

10/31/2013	$	379	$	(340	)	$	-		$	39
2/5/2014		715		(649	)		-			66
7/24/2014 Series A		2,415		(1,573	)		(842	)		-
7/24/2014 Series B		1,726		(1,713	)		(13	)		-
6/22/2015		1,807		(1,121	)		(686	)		-

Total	$	7,042	$	(5,396	)	$	(1,541	)	$	105

Issuance Date	January 1, 2015		Initial Measurements		Reclassed from Equity		Increase (Decrease) in Fair Value			December 31, 2015

10/31/2013	$	233	$	-	$	-	$	146		$	379
2/5/2014		266		-		-		449			715
7/24/2014 Series A		-		-		3,452		(1,037	)		2,415
7/24/2014 Series B		-		-		1,947		(221	)		1,726
6/22/2015		-		2,958		-		(1,151	)		1,807

Total	$	499	$	2,958	$	5,399	$	(1,814	)	$	7,042

Schedule of Warrants Subject to Remeasurement

Number of Warrants Subject to Remeasurement:

Issuance Date	December 31, 2015	Reductions	December 31, 2016

10/31/2013	685,715	-	685,715
2/5/2014	1,329,731	-	1,329,731
7/24/2014 Series A	4,288,500	(4,288,500)	-
7/24/2014 Series B	4,795,321	(4,795,321)	-
6/22/2015	3,000,000	(3,000,000)	-

Total	14,099,267	(12,083,821)	2,015,446

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2016

Stockholders' Equity [Abstract]

Summary of Outstanding Common Stock Warrants

Outstanding common stock warrants consist of the following:

Issue Date	Expiration Date	Total Warrants		Exercise Price

4/26/2013	4/26/2018		69,321	$	11.18
10/31/2013	4/30/2019		685,715	$	0.75
2/5/2014	2/5/2019		1,329,731	$	0.75
7/24/2014	7/24/2019		6,198,832	$	0.75 - $ 2.45
6/22/2015	6/22/2020		3,000,000	$	0.75
12/30/2015	12/30/2020		650,442	$	1.13
1/29/2016	1/29/2021		99,057	$	1.06
			12,033,098

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Stock-based compensation (Tables)

12 Months Ended

Dec. 31, 2016

Stock-based compensation [Abstract]

Schedule of Stock Option Plans

A summary of option transactions for all of the Company's stock options during the years ended December 31, 2016 and 2015 follows:

	Number of Stock Options			Weighted Average Exercise Price
Outstanding at December 31, 2014		1,308,835		$	2.76
Granted		1,487,500			1.15
Exercised		-			-
Expired/cancelled		(111,983	)		10.70
Outstanding at December 31, 2015		2,684,352			1.54
Granted		2,340,000			0.58
Exercised		-			-
Expired/cancelled		(523,830	)		2.07
Outstanding at December 31, 2016		4,500,522		$	1.02
Exercisable at December 31, 2016		2,200,672		$	1.48
Options expected to vest at December 31, 2016		2,049,850		$	0.59

Schedule of Stock Options Outstanding

The outstanding and exercisable options at December 31, 2016, have a range of exercise prices and associated weighted remaining contractual life and weighted average exercise price, as follows:

Options Range of Exercise Prices		Outstanding Number of Shares		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Exercisable Number of Shares		Exercisable Weighted Avg. Exercise Price
$	0 - $1.25		3,827,500		9.41	$	0.80		1,530,000	$	1.14
$	1.26 - $5.00		625,000		7.93		1.58		625,000		1.58
$	5.01 - $10.00		36,022		6.78		7.06		34,597		7.08
$	10.01 - $63.00		12,000		5.60		24.19		11,075		24.27
Total			4,500,522		9.17	$	1.02		2,200,672	$	1.48

Schedule of Fair Value of Each Option Award Granted

The fair value of each option award granted during the period is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

	Years Ended December 31,
	2016	2015
Risk-free interest rate	1.51 – 2.18%	1.80 - 1.90%
Volatility	50.00%	50.00 - 85.68%
Expected dividend yield	0%	0%
Expected life	6.5 years	6.5 years
Estimated forfeiture rate	0%	0%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income taxes [Abstract]

Components of Income Tax Expense (Benefit)

	Year Ended December 31,
	2016			2015
Current:
Federal	$	-		$	-
State		15			-
		15			-
Deferred
Federal		(4,119	)		3,302
State		(648	)		388
		(4,767	)		3,690
Valuation allowance		5,007			(3,571	)
Income tax expense	$	255		$	119

Computation of U.S. Federal Income Tax Rate to Pretax Loss from Continuing Operations

The difference between the actual income tax benefit and that computed by applying the U.S. federal income tax rate of 34% to pretax loss from continuing operations is summarized below:

	For the Years Ended December 31,
	2016			2015

Computed expected tax benefit	$	(1,047	)	$	(8,472	)
State tax benefit, net of federal effect		(499	)		(1,365	)
Warrant value fluctuation		(1,835	)		3,271
Net increase in valuation allowance		3,636			6,685
Provision for income taxes	$	255		$	119

Summary of Deferred Tax Assets and Liabilities

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2016 and 2015 are as follows:

	December 31,
	2016			2015

Deferred tax assets/(liabilities):
Net operating loss carryforward	$	72,870		$	64,075
Capitalized research and developmental costs		8,711			10,543
Inventory		149			47
Reserves & accrued expenses		291			3,295
Convertible debt discount		(11,097	)		(11,182	)
Property & equipment		432			(355	)
Non-cash compensation		1,127			1,054
Goodwill		(359	)		(119	)
Total deferred tax assets		72,124			67,358
Less: valuation allowance		(72,483	)		(67,477	)
Net deferred tax assets/(liabilities)	$	(359	)	$	(119	)

Business Segments and Geographic Data (Tables)

12 Months Ended

Dec. 31, 2016

Business Segments and Geographic Data [Abstract]

Schedule of Segment Reporting Information by Segment

The following tables reflect results of operations from our business segments for the periods indicated below:

Year Ended December 31, 2016

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	24,558		$	7,065		$	134		$	31,757
Costs of revenues		8,763			3,506			367			12,636
Gross profit		15,795			3,559			(233	)		19,121
Gross profit %		64.3	%		50.4	%		(173.9	%)		60.2	%

Allocated operating expenses:
Engineering and product development		1,288			210			431			1,929
Selling and marketing expenses		12,591			375			186			13,152

Unallocated operating expenses		-			-			-			7,637
		13,879			585			617			22,718
Income (loss) from operations		1,916			2,974			(850	)		(3,597	)

Interest expense, net		-			-			-			(4,900	)
Change in fair value of warrant liability		-			-			-			5,396
Other income (expense), net		-			-			-			21

Income (loss) before income taxes	$	1,916		$	2,974		$	(850	)	$	(3,080	)

Year Ended December 31, 2015

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	14,616		$	3,591		$	288		$	18,495
Costs of revenues		4,680			1,989			7,050			13,719
Gross profit		9,936			1,602			(6,762	)		4,776
Gross profit %		68.0	%		44.6	%		(2347.8	%)		25.8	%

Allocated operating expenses:
Engineering and product development		676			104			1,249			2,029
Selling and marketing expenses		7,128			193			1,873			9,194

Unallocated operating expenses		-			-			-			10,028
		7,804			297			3,122			21,251
Income (loss) from operations		2,132			1,305			(9,884	)		(16,475	)

Interest expense, net		-			-			-			(10,200	)
Change in fair value of warrant liability		-			-			-			1,814
Other income (expense), net		-			-			-			33

Income (loss) before income taxes	$	2,132		$	1,305		$	(9,884	)	$	(24,828	)

Schedule of Net Revenues by Geographic Areas

For the year ended December 31, 2016 and 2015 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows:

	Years Ended December 31,
	2016		2015
Domestic	$	25,536	$	14,724
Foreign		6,221		3,771
	$	31,757	$	18,495

Summary of Total Assets by Reportable Segment

As of December 31, 2016 and 2015, total assets by reportable segment were as follows:

	December 31,
Assets:	2016		2015
Dermatology Recurring Procedures	$	34,612	$	40,420
Dermatology Procedures Equipment		3,980		5,364
Dermatology Imaging		265		661
Other unallocated assets		4,336		3,634
Consolidated total	$	43,193	$	50,079

The Company (Details) $ in Thousands		3 Months Ended	12 Months Ended
The Company (Details) $ in Thousands	Jun. 22, 2015 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2016 USD ($) Systems Channel shares	Dec. 31, 2015 USD ($) shares
Liquidity [Abstract]
Accumulated deficit			$ (210,575)	$ (207,240)
Reverse stock-split ratio			0.10
Revenue Recognition [Abstract]
Number of distribution channels \| Channel			2
Accounts Receivable, Net [Abstract]
Allowance for doubtful accounts			$ 135	45
Inventories [Abstract]
Reserves on inventory			257
Inventory write-offs			$ 0	4,818
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			5 years
Write-down, property and equipment		$ 920	$ 0	920
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets			0
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt			20,082	15,958
Product Warranty Accrual [Roll Forward]
Accrual at beginning of year			226	48
Acquired in asset purchase			0	265
Additions charged to warranty expense			196	98
Expiring warranties/claimed satisfied			(307)	(185)
Total			115	226
Less: current portion			(102)	(168)
Accrued warranty, non-current portion			13	58
Earnings Per Share [Abstract]
Net loss			(3,335)	(27,909)
Gain on the change in fair value of the warrant liability			(5,396)	$ (1,814)
Diluted loss			$ (8,731)
Weighted average number of common and common equivalent shares outstanding [Abstract]
Basic number of common shares outstanding (in shares) \| shares			10,595,068	8,536,699
Dilutive effect of warrants (in shares) \| shares			983,505
Diluted number of common and common stock equivalent shares outstanding (in shares) \| shares			11,578,573	8,536,699
Advertising Costs [Abstract]
Advertising expense			$ 4,389	$ 2,500
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares			64,981,515	68,384,707
Minimum [Member]
Product Warranty Liability [Line Items]
Standard warranty period			1 year
Offered warranty period			3 years
Maximum [Member]
Product Warranty Liability [Line Items]
Standard warranty period			2 years
Offered warranty period			4 years
Computer Hardware and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			3 years
Computer Hardware and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			7 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			3 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			7 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			7 years
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability (Note 12)			$ 105	$ 7,042
Fair Value, Measurements, Recurring [Member] \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability (Note 12)			0	0
Fair Value, Measurements, Recurring [Member] \| Significant other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability (Note 12)			0	0
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability (Note 12)			$ 105	$ 7,042
Patents and Licensed Technologies [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			8 years
Patents and Licensed Technologies [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			12 years
Core Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			10 years
Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			5 years
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			10 years
XTRAC and VTRAC [Member]
Business Acquisition [Line Items]
Acquisition price	$ 42,528
XTRAC and VTRAC [Member] \| Core Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			10 years
XTRAC and VTRAC [Member] \| Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			5 years
XTRAC [Member]
Business Acquisition [Line Items]
Number of systems placed in dermatologists offices \| Systems			775
Common Stock Equivalents of Convertible Debentures [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares			46,105,715	46,435,127
Common Stock Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares			12,033,098	16,729,362
Common Stock Equivalents of Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares			2,339,180	2,535,866
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares			4,503,522	2,684,352

Acquisition (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 22, 2015	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Return amount from escrow account of purchase price		$ 125
Aggregate Fair Value of Assets Acquired and the Liabilities Assumed [Abstract]
Goodwill		$ 8,803	$ 8,928
Product Technology [Member]
Business Acquisition [Line Items]
Estimated useful life		5 years
Core Technology [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years
Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years
Customer Relationships [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years
XTRAC and VTRAC [Member]
Business Acquisition [Line Items]
Acquisition price	$ 42,528
Return amount from escrow account of purchase price	125
Aggregate Fair Value of Assets Acquired and the Liabilities Assumed [Abstract]
Current assets	7,233
Property, plant and equipment	14,340
Identifiable intangible assets	16,100
Other assets	45
Total assets assumed	37,718
Current liabilities	(3,945)
Note payable	(57)
Other long term liabilities	(116)
Total liabilities assumed	(4,118)
Net assets acquired	33,600
Goodwill	$ 8,803
Unaudited Pro-forma Results [Abstract]
Net revenues			33,163
Net loss attributable to common stockholders			$ (34,252)
Net loss per basic and diluted share: (in dollars per share)			$ (4.01)
Shares used in calculating net loss per basic and diluted share: (in shares)			8,536,699
XTRAC and VTRAC [Member] \| Product Technology [Member]
Business Acquisition [Line Items]
Estimated useful life		5 years
XTRAC and VTRAC [Member] \| Core Technology [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years
XTRAC and VTRAC [Member] \| Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years
XTRAC and VTRAC [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years

Inventories (Details) - USD ($) $ in Thousands	12 Months Ended
Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Schedule of inventory [Abstract]
Raw materials and work in progress	$ 2,440	$ 3,706
Finished goods	377	422
Inventories, net	2,817	4,128
Inventory [Line Items]
Excess and obsolete inventories write off	0	$ 4,818
Reserve for obsolete inventory	257
MelaFind Systems [Member]
Inventory [Line Items]
Excess and obsolete inventories write off	5,688
Reserve for obsolete inventory	$ 870

Property and Equipment, net (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 17,008	$ 20,012
Accumulated depreciation and amortization		(6,828)	(6,161)
Property and equipment, net		10,180	13,851
Depreciation and related amortization expense		4,551	3,141
Impairment of long-lived assets	$ 920	0	920
Net book value written off		124	0
Irvington New York facility [Member]
Property, Plant and Equipment [Line Items]
Amount of disposed of leasehold improvements, machinery and equipment and furniture and fixtures		3,933
Amount of accumulated depreciation and amortization		(3,809)
Lasers Placed-In-Service [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		16,712	15,783
Equipment, Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		160	1,219
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		111	2,080
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 25	$ 931

Patents and Licensed Technologies, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, net	$ 6,272	$ 7,247
Estimated amortization expense [Abstract]
Patents and licensed technologies, net	6,272	7,247
Core Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	$ 5,974	5,974
Estimated useful life	10 years
Core Technology [Member] \| XTRAC and VTRAC [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, net	$ 5,700
Estimated useful life	10 years
Estimated amortization expense [Abstract]
Patents and licensed technologies, net	$ 5,700
Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	$ 2,000	2,000
Estimated useful life	5 years
Product Technology [Member] \| XTRAC and VTRAC [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, net	$ 2,000
Estimated useful life	5 years
Estimated amortization expense [Abstract]
Patents and licensed technologies, net	$ 2,000
Patents and Licensed Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	7,974	7,974
Accumulated amortization	(1,702)	(727)
Patents and licensed technologies, net	6,272	7,247
Amortization expense	975	490
Estimated amortization expense [Abstract]
2017	975
2018	975
2019	975
2020	775
2021	575
Thereafter	1,997
Patents and licensed technologies, net	$ 6,272	$ 7,247

Goodwill (Details) $ in Thousands	12 Months Ended
Goodwill (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Goodwill [Roll Forward]
Balance at beginning of period	$ 8,928
Return of purchase price from escrow	(125)
Balance at end of period	8,803
Accumulated impairment losses of goodwill	0
Dermatology Recurring Procedures [Member]
Goodwill [Roll Forward]
Balance at end of period	7,958
Dermatology Procedures Equipment [Member]
Goodwill [Roll Forward]
Balance at end of period	$ 845

Other Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
Other Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, net	$ 7,140	$ 7,980
Estimated amortization expense [Abstract]
Other intangible assets, net	7,140	7,980
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, gross	$ 6,900	6,900
Estimated useful life	10 years
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, gross	$ 1,500	1,500
Estimated useful life	10 years
Customer Relationships and Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, gross	$ 8,400	8,400
Accumulated amortization	(1,260)	(420)
Other intangible assets, net	7,140	7,980
Amortization expense of other intangible assets	840	420
Estimated amortization expense [Abstract]
2017	840
2018	840
2019	840
2020	840
2021	840
Thereafter	2,940
Other intangible assets, net	$ 7,140	$ 7,980

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other Accrued Liabilities [Abstract]
Accrued warranty, current, see Note 1	$ 102	$ 168
Accrued compensation, including commissions and vacation	1,177	1,336
Accrued sales and other taxes	439	349
Accrued professional fees and other accrued liabilities	274	308
Total other accrued liabilities	$ 1,992	$ 2,161

Convertible Debentures (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Jul. 21, 2014 USD ($) shares $ / shares	Dec. 31, 2016 USD ($) shares $ / shares	Dec. 31, 2015 USD ($) $ / shares	Oct. 29, 2013 $ / shares shares
Debt Instrument [Line Items]
Total convertible debt		$ 12,028	$ 9,839
Common stock, par value (in dollars per share) \| $ / shares		$ 0.001	$ 0.001
Fair value of warrants adjustment (income) expense		$ (5,396)	$ (1,814)
Debentures converted in shares of common stock, value		265	4,815
Interest expense on debt		217
Debentures outstanding amount		$ 40,727
Maximum [Member]
Debt Instrument [Line Items]
Discounted cash flow change		10.00%
Series A Warrants [Member]
Debt Instrument [Line Items]
Number of warrants to purchase common stock (in shares) \| shares	6,198,832			685,715
Exercise price of warrants (in dollars per share) \| $ / shares				$ 8.50
Senior Secured 2.25% Convertible Debentures [Member]
Debt Instrument [Line Items]
Total convertible debt		$ 7,174	5,489
Interest rate		2.25%
Debt instrument, unamortized discount		$ 24,314	26,267
Deferred financing costs		524	522
Aggregate principal amount of debt		$ 32,500
Number of shares debt convertible (in shares) \| shares		43,333,334
Initial conversion price (in dollars per share) \| $ / shares		$ 0.75
Maturity period		5 years
Maturity date		Jun. 30, 2021
Debt instrument, convertible, beneficial conversion feature		$ 27,300
Senior Secured 2.25% Convertible Debentures [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Initial conversion price (in dollars per share) \| $ / shares		$ 0.75
Senior Secured 2.25% Convertible Debentures [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Initial conversion price (in dollars per share) \| $ / shares		$ 1.38
Senior Secured 4% Convertible Debentures [Member]
Debt Instrument [Line Items]
Total convertible debt		$ 4,854	4,350
Interest rate		4.00%
Debt instrument, unamortized discount	$ 10,353	$ 3,469	3,922
Deferred financing costs		392	$ 443
Aggregate principal amount of debt	$ 15,000	$ 15,000
Number of shares debt convertible (in shares) \| shares	5,847,955	5,847,955
Initial conversion price (in dollars per share) \| $ / shares	$ 2.565	$ 2.565
Maturity period		5 years
Maturity date		Jun. 30, 2021
Debt instrument, convertible, beneficial conversion feature	$ 4,565
Fair value of warrants	5,296
Fair value of warrants adjustment (income) expense	491
Debt instrument initial carrying amount	$ 4,647
Debentures converted in shares of common stock, value		$ 265
Debt conversion, converted instrument, issued (in shares) \| shares		354,411
Senior Secured 4% Convertible Debentures [Member] \| Series A Warrants [Member]
Debt Instrument [Line Items]
Number of warrants to purchase common stock (in shares) \| shares		6,198,832
Exercise price of warrants (in dollars per share) \| $ / shares	$ 2.45
Maturity date		Jul. 01, 2019
Common stock, par value (in dollars per share) \| $ / shares	$ 0.001

Long-term Debt (Details) $ / shares in Units, $ in Thousands			12 Months Ended
	Jan. 29, 2016 USD ($) $ / shares shares	Dec. 30, 2015 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) Tranche	Dec. 31, 2015 USD ($)
Long-term Debt [Abstract]
Term note, net of debt discount of $258 and $287, respectively; and deferred financing cost of $276 and $306, respectively			$ 40,727
Less: current portion			(1,714)	$ 0
Long-term debt			9,752	9,851
Repayment of debt			0	(10,000)
Term-Note Credit Facility [Member]
Long-term Debt [Abstract]
Term note, net of debt discount of $258 and $287, respectively; and deferred financing cost of $276 and $306, respectively			11,466	9,851
Less: current portion			(1,714)	0
Long-term debt			9,752	9,851
Unamortized discount on the long term debt			258	287
Deferred financing costs			276	306
Maturities of Long-term Debt [Abstract]
2017			1,714
2018			3,429
2019			3,429
2020			3,428
Total long-term debt			12,000
Assumptions used to value the warrants [Abstract]
Number of shares underlying warrants (in shares) \| shares	99,057	650,442
Exercise price (in dollars per share) \| $ / shares	$ 1.06	$ 1.13
Share price (in dollars per share) \| $ / shares	$ 1.05	$ 1.11
Fair value of warrants	$ 47	$ 321
Volatility	50.00%	50.00%
Risk-free interest rate	1.80%	1.80%
Expected dividend yield	0.00%	0.00%
Expected warrant life	5 years	5 years
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member]
Long-term Debt [Abstract]
Unamortized discount on the long term debt and deferred financing costs			534	$ 649
Maximum borrowing capacity under the agreement			$ 12,000
Number of tranches \| Tranche			2
Repayment term			60 months
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| LIBOR [Member]
Long-term Debt [Abstract]
Interest rate on credit facility			8.25%
LIBOR floor Rate			0.50%
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| First Tranche [Member]
Long-term Debt [Abstract]
Proceeds from credit facility		$ 10,500
Repayment of debt		$ (10,000)
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| Second Tranche [Member]
Long-term Debt [Abstract]
Proceeds from credit facility	$ 1,500

Commitments and Contingencies (Details) $ in Thousands	12 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2016 USD ($) Lease	Dec. 31, 2015 USD ($)
Commitments and Contingencies [Abstract]
Number of operating leases \| Lease	3
Rent expense charged to operations	$ 783	$ 748
Future Annual Minimum Payments under Operating Leases [Abstract]
2017	432
2018	220
Total	$ 652

Warrants (Details) $ / shares in Units, $ in Thousands			12 Months Ended
Warrants (Details) $ / shares in Units, $ in Thousands	Jun. 22, 2016 $ / shares shares	Jul. 21, 2014 shares	Dec. 31, 2016 USD ($) shares $ / shares	Dec. 31, 2015 USD ($) $ / shares shares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value of warrants adjustment (income) expense			$ (5,396)	$ (1,814)
7/24/2014 Series A [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares) \| shares		6,198,832
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value of warrants adjustment (income) expense				$ (1,814)
Fair Value Assumptions [Abstract]
Number of shares underlying warrants (in shares) \| shares	12,083,821		2,015,446	14,099,267
Stock price (in dollars per share) \| $ / shares	$ 0.65		$ 0.44	$ 1.11
Volatility			47.00%
Risk-free interest rate			1.22%
Expected dividend yield	0.00%		0.00%	0.00%
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares) \| shares			14,099,267
Reductions \| shares			(12,083,821)
Number of warrants to purchase common stock (in shares) \| shares			2,015,446	14,099,267
Warrant [Member] \| Minimum [Member]
Fair Value Assumptions [Abstract]
Volatility	35.00%			35.90%
Risk-free interest rate	0.25%			0.02%
Expected warrant life	1 month 2 days		2 years 1 month 13 days	25 days
Warrant [Member] \| Maximum [Member]
Fair Value Assumptions [Abstract]
Volatility	50.00%			50.00%
Risk-free interest rate	1.04%			1.63%
Expected warrant life	4 years		2 years 4 months 6 days	4 years 5 months 23 days
Warrant [Member] \| 10/31/2013 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares) \| shares			685,715
Reductions \| shares			0
Number of warrants to purchase common stock (in shares) \| shares			685,715	685,715
Warrant [Member] \| 2/5/2014 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares) \| shares			1,329,731
Reductions \| shares			0
Number of warrants to purchase common stock (in shares) \| shares			1,329,731	1,329,731
Warrant [Member] \| 7/24/2014 Series A [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares) \| shares			4,288,500
Reductions \| shares			(4,288,500)
Number of warrants to purchase common stock (in shares) \| shares			0	4,288,500
Warrant [Member] \| 7/24/2014 Series B [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares) \| shares			4,795,321
Reductions \| shares			(4,795,321)
Number of warrants to purchase common stock (in shares) \| shares			0	4,795,321
Warrant [Member] \| 6/22/2015 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares) \| shares			3,000,000
Reductions \| shares			(3,000,000)
Number of warrants to purchase common stock (in shares) \| shares			0	3,000,000
Warrant [Member] \| Level 3 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			$ 7,042	$ 499
Initial measurements				2,958
Reclassed from equity			(1,541)	5,399
Increase (decrease) in fair value			(5,396)	(1,814)
Balance as end of period			105	7,042
Warrant [Member] \| Level 3 [Member] \| 10/31/2013 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			379	233
Initial measurements				0
Reclassed from equity			0	0
Increase (decrease) in fair value			(340)	146
Balance as end of period			39	379
Warrant [Member] \| Level 3 [Member] \| 2/5/2014 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			715	266
Initial measurements				0
Reclassed from equity			0	0
Increase (decrease) in fair value			(649)	449
Balance as end of period			66	715
Warrant [Member] \| Level 3 [Member] \| 7/24/2014 Series A [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			2,415	0
Initial measurements				0
Reclassed from equity			(842)	3,452
Increase (decrease) in fair value			(1,573)	(1,037)
Balance as end of period			0	2,415
Warrant [Member] \| Level 3 [Member] \| 7/24/2014 Series B [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			1,726	0
Initial measurements				0
Reclassed from equity			(13)	1,947
Increase (decrease) in fair value			(1,713)	(221)
Balance as end of period			0	1,726
Warrant [Member] \| Level 3 [Member] \| 6/22/2015 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			1,807	0
Initial measurements				2,958
Reclassed from equity			(686)	0
Increase (decrease) in fair value			(1,121)	(1,151)
Balance as end of period			$ 0	$ 1,807

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Jul. 24, 2014	Feb. 05, 2014	Oct. 29, 2013	Dec. 31, 2016	Dec. 31, 2014	Dec. 31, 2015	Jul. 21, 2014
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)				10,000,000		10,000,000
Preferred stock, par value (in dollars per share)				$ 0.10		$ 0.10
Preferred stock, shares issued (in shares)				6,000		6,505
Preferred stock, shares outstanding (in shares)				6,000		6,505
Liquidated damages paid to purchasers					$ 3,420
Total preferred stock value				$ 1		$ 1
Common stock, shares authorized (in shares)				150,000,000		150,000,000
Common stock, par value (in dollars per share)				$ 0.001		$ 0.001
Common stock, shares issued (in shares)			422,819	10,834,490		10,283,393
Common stock, shares outstanding (in shares)				10,834,490		10,283,393
Proceeds from issuance of common stock			$ 6,000,000
Class of Warrant or Right [Line Items]
Total Warrants (in shares)				12,033,098
Series A Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)			$ 8.50
Warrants issued and outstanding to purchase common stock (in shares)			685,715				6,198,832
Series B warrants [Member]
Class of Warrant or Right [Line Items]
Warrants issued and outstanding to purchase common stock (in shares)			434,325
Common Stock Warrant One [Member]
Class of Warrant or Right [Line Items]
Warrants Issue Date				Apr. 26, 2013
Warrant Expiration Date				Apr. 26, 2018
Total Warrants (in shares)				69,321
Exercise price (in dollars per share)				$ 11.18
Common Stock Warrant Two [Member]
Class of Warrant or Right [Line Items]
Warrants Issue Date				Oct. 31, 2013
Warrant Expiration Date				Apr. 30, 2019
Total Warrants (in shares)				685,715
Exercise price (in dollars per share)				$ 0.75
Common Stock Warrant Three [Member]
Class of Warrant or Right [Line Items]
Warrants Issue Date				Feb. 05, 2014
Warrant Expiration Date				Feb. 05, 2019
Total Warrants (in shares)				1,329,731
Exercise price (in dollars per share)				$ 0.75
Common Stock Warrant Four [Member]
Class of Warrant or Right [Line Items]
Warrants Issue Date				Jul. 24, 2014
Warrant Expiration Date				Jul. 24, 2019
Total Warrants (in shares)				6,198,832
Common Stock Warrant Four [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)				$ 0.75
Common Stock Warrant Four [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)				$ 2.45
Common Stock Warrant Five [Member]
Class of Warrant or Right [Line Items]
Warrants Issue Date				Jun. 22, 2015
Warrant Expiration Date				Jun. 22, 2020
Total Warrants (in shares)				3,000,000
Exercise price (in dollars per share)				$ 0.75
Common Stock Warrant Six [Member]
Class of Warrant or Right [Line Items]
Warrants Issue Date				Dec. 30, 2015
Warrant Expiration Date				Dec. 30, 2020
Total Warrants (in shares)				650,442
Exercise price (in dollars per share)				$ 1.13
Common Stock Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Warrants Issue Date				Jan. 29, 2016
Warrant Expiration Date				Jan. 29, 2021
Total Warrants (in shares)				99,057
Exercise price (in dollars per share)				$ 1.06
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)				6,000		6,505
Preferred stock, shares outstanding (in shares)				6,000		6,505
Number of preferred stock converted (in shares)	12,300			504.5
Conversion of convertible preferred stock, stated value (in dollars per share)	$ 1,000
Initial conversion price (in dollars per share)	$ 2.565
Total preferred stock value	$ 2,487
Intrinsic value of beneficial conversion feature	$ 1,887
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)	$ 2.45
Warrants issued and outstanding to purchase common stock (in shares)	4,795,321
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)		$ 0.10
Preferred stock, shares issued (in shares)		12,300
Number of preferred stock converted (in shares)	12,300
Conversion of convertible preferred stock, stated value (in dollars per share)		$ 1,000
Common Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock (in shares)	4,795,321			196,686
Common Stock Equivalents of Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)		$ 0.10
Preferred stock, shares issued (in shares)		12,300
Convertible preferred stock (in shares)		1,464,287
Initial conversion price (in dollars per share)		$ 8.40
Proceeds from issuance of warrants		$ 11,458
Warrant term		5 years
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)		$ 7.40
Warrants issued and outstanding to purchase common stock (in shares)		1,329,731

Stock-based compensation (Details) - $ / shares	12 Months Ended
Stock-based compensation (Details) - $ / shares	Dec. 31, 2016	Dec. 31, 2015	Oct. 27, 2016
Stock Options [Member]
Number of Stock Options [Roll Forward]
Outstanding at beginning period (in shares)	2,684,352	1,308,835
Granted (in shares)	2,340,000	1,487,500
Exercised (in shares)	0	0
Expired/cancelled (in shares)	(523,830)	(111,983)
Outstanding at end of period (in shares)	4,500,522	2,684,352
Exercisable at end of period (in shares)	2,200,672
Options expected to vest at end of period (in shares)	2,049,850
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 1.54	$ 2.76
Granted (in dollars per share)	0.58	1.15
Exercised (in dollars per share)	0	0
Expired/cancelled (in dollars per share)	2.07	10.70
Outstanding at end of period (in dollars per share)	1.02	$ 1.54
Exercisable at end of period (in dollars per share)	1.48
Options expected to vest at end of period (in dollars per share)	$ 0.59
Stock Incentive Plan 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)	8,294,400		10,294,400

Stock-based compensation, Stock Options Plan by Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding number of shares (in shares) \| shares	4,500,522
Weighted average remaining contractual life	9 years 2 months 1 day
Weighted average exercise price (in dollars per share)	$ 1.02
Exercisable number of shares (in shares) \| shares	2,200,672
Exercisable weighted average exercise price (in dollars per share)	$ 1.48
$0 - $1.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	0
Upper range limit (in dollars per share)	$ 1.25
Outstanding number of shares (in shares) \| shares	3,827,500
Weighted average remaining contractual life	9 years 4 months 28 days
Weighted average exercise price (in dollars per share)	$ 0.80
Exercisable number of shares (in shares) \| shares	1,530,000
Exercisable weighted average exercise price (in dollars per share)	$ 1.14
$1.26 - $5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	1.26
Upper range limit (in dollars per share)	$ 5.00
Outstanding number of shares (in shares) \| shares	625,000
Weighted average remaining contractual life	7 years 11 months 5 days
Weighted average exercise price (in dollars per share)	$ 1.58
Exercisable number of shares (in shares) \| shares	625,000
Exercisable weighted average exercise price (in dollars per share)	$ 1.58
$5.01 - $10.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	5.01
Upper range limit (in dollars per share)	$ 10.00
Outstanding number of shares (in shares) \| shares	36,022
Weighted average remaining contractual life	6 years 9 months 11 days
Weighted average exercise price (in dollars per share)	$ 7.06
Exercisable number of shares (in shares) \| shares	34,597
Exercisable weighted average exercise price (in dollars per share)	$ 7.08
$10.01 - $63.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	10.01
Upper range limit (in dollars per share)	$ 63.00
Outstanding number of shares (in shares) \| shares	12,000
Weighted average remaining contractual life	5 years 7 months 6 days
Weighted average exercise price (in dollars per share)	$ 24.19
Exercisable number of shares (in shares) \| shares	11,075
Exercisable weighted average exercise price (in dollars per share)	$ 24.27

Stock-based compensation, Fair Value Assumptions (Details) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Dec. 06, 2016	Oct. 31, 2016	Jun. 07, 2016	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate - Minimum				1.51%	1.80%
Risk-free interest rate - Maximum				2.18%	1.90%
Volatility				50.00%
Volatility - Minimum					50.00%
Volatility - Maximum					85.68%
Expected dividend yield				0.00%	0.00%
Expected life				6 years 6 months	6 years 6 months
Estimated forfeiture rate				0.00%	0.00%
Stock-based compensation expense				$ 113	$ 1,753
Unrecognized compensation expense				$ 371
Weighted average period of recognition				1 year 3 months 18 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Share price (in dollars per share)				$ 0.44
Term of vesting			4 years
Expiry period of option			10 years
Shares issued (in shares)			340,000
Purchase price (in dollars per share)			$ 0.75
Aggregate fair value of shares issued			$ 128
Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expiry period of option				10 years
Stock Options [Member] \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Term of vesting		3 years
Shares issued (in shares)		542,500		1,007,500
Purchase price (in dollars per share)		$ 0.55		$ 0.55
Aggregate fair value of shares issued		$ 150
Stock Options [Member] \| Non-Employee Board Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Term of vesting	1 year
Expiry period of option	10 years	10 years
Shares issued (in shares)	450,000
Purchase price (in dollars per share)	$ 0.55
Aggregate fair value of shares issued	$ 182

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current [Abstract]
Federal	$ 0	$ 0
State	15	0
Current income taxes	15	0
Deferred [Abstract]
Federal	(4,119)	3,302
State	(648)	388
Deferred income tax	(4,767)	3,690
Valuation allowance	5,007	(3,571)
Income tax expense	$ 255	119
Effective income tax rate	34.00%
Difference between income tax benefit and U.S. federal income tax rate to pretax loss from continuing operations [Abstract]
Computed expected tax benefit	$ (1,047)	(8,472)
State tax benefit, net of federal effect	(499)	(1,365)
Warrant value fluctuation	(1,835)	3,271
Net increase in valuation allowance	3,636	6,685
Income tax expense	255	119
Deferred tax assets/(liabilities) [Abstract]
Net operating loss carryforward	72,870	64,075
Capitalized research and developmental costs	8,711	10,543
Inventory	149	47
Reserves & accrued expenses	291	3,295
Convertible debt discount	(11,097)	(11,182)
Property & equipment	432
Property & equipment		(355)
Non-cash compensation	1,127	1,054
Goodwill	(359)	(119)
Total deferred tax assets	72,124	67,358
Less: valuation allowance	(72,483)	(67,477)
Net deferred tax assets/(liabilities)	(359)	(119)
Valuation allowance - Deferred tax asset change in amount	5,035	(3,571)
Federal operating loss carryforwards, net	$ 183,727	$ 163,837
Earliest open tax year subject to examination	2011

Business Segments and Geographic Data (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($) Segment	Dec. 31, 2015 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments \| Segment	3
Number of dermatology procedures segments \| Segment	2
Results of Operations from Business Segments [Abstract]
Revenues	$ 31,757	$ 18,495
Cost of revenues	12,636	13,719
Gross profit	$ 19,121	$ 4,776
Gross profit %	60.20%	25.80%
Allocated operating expenses [Abstract]
Engineering and product development	$ 1,929	$ 2,029
Selling and marketing expenses	13,152	9,194
Unallocated operating expenses	7,637	10,028
Total operating expenses	22,718	21,251
Income (loss) from operations	(3,597)	(16,475)
Interest expense, net	(4,900)	(10,200)
Change in fair value of warrant liability	5,396	1,814
Other income (expense), net	21	33
Income (loss) before income taxes	(3,080)	(24,828)
Assets	$ 43,193	$ 50,079
Long Lived Assets [Member] \| Geographic Concentration Risk [Member] \| Domestic [Member]
Allocated operating expenses [Abstract]
Concentration risk percentage	100.00%	100.00%
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	$ 24,558	$ 14,616
Cost of revenues	8,763	4,680
Gross profit	$ 15,795	$ 9,936
Gross profit %	64.30%	68.00%
Allocated operating expenses [Abstract]
Engineering and product development	$ 1,288	$ 676
Selling and marketing expenses	12,591	7,128
Unallocated operating expenses	0	0
Total operating expenses	13,879	7,804
Income (loss) from operations	1,916	2,132
Interest expense, net	0	0
Change in fair value of warrant liability	0	0
Other income (expense), net	0	0
Income (loss) before income taxes	1,916	2,132
Assets	34,612	40,420
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	7,065	3,591
Cost of revenues	3,506	1,989
Gross profit	$ 3,559	$ 1,602
Gross profit %	50.40%	44.60%
Allocated operating expenses [Abstract]
Engineering and product development	$ 210	$ 104
Selling and marketing expenses	375	193
Unallocated operating expenses	0	0
Total operating expenses	585	297
Income (loss) from operations	2,974	1,305
Interest expense, net	0	0
Change in fair value of warrant liability	0	0
Other income (expense), net	0	0
Income (loss) before income taxes	2,974	1,305
Assets	3,980	5,364
Operating Segments [Member] \| Dermatology Imaging [Member]
Results of Operations from Business Segments [Abstract]
Revenues	134	288
Cost of revenues	367	7,050
Gross profit	$ (233)	$ (6,762)
Gross profit %	(173.90%)	(2347.80%)
Allocated operating expenses [Abstract]
Engineering and product development	$ 431	$ 1,249
Selling and marketing expenses	186	1,873
Unallocated operating expenses	0	0
Total operating expenses	617	3,122
Income (loss) from operations	(850)	(9,884)
Interest expense, net	0	0
Change in fair value of warrant liability	0	0
Other income (expense), net	0	0
Income (loss) before income taxes	(850)	(9,884)
Assets	265	661
Reportable Geographical Components [Member] \| Domestic [Member]
Results of Operations from Business Segments [Abstract]
Revenues	25,536	14,724
Reportable Geographical Components [Member] \| Foreign [Member]
Results of Operations from Business Segments [Abstract]
Revenues	6,221	3,771
Other Unallocated Assets [Member]
Allocated operating expenses [Abstract]
Assets	$ 4,336	$ 3,634

Related Parties (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Nov. 04, 2015 USD ($)	Dec. 31, 2016 USD ($) shares $ / shares
Senior Secured 2.25% Convertible Debentures [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt		$ 32,500
Interest rate		2.25%
Number of shares debt convertible (in shares) \| shares		43,333,334
Initial conversion price (in dollars per share) \| $ / shares		$ 0.75
Maturity period		5 years
Maturity date		Jun. 30, 2021
Sabby Management LLC and Broadfin LLC [Member] \| Senior Secured 2.25% Convertible Debentures [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt		$ 32,500
Interest rate		2.25%
Number of shares underlying warrants (in shares) \| shares		3,000,000
Exercise price of warrants (in dollars per share) \| $ / shares		$ 0.75
Number of shares debt convertible (in shares) \| shares		43,333,334
Initial conversion price (in dollars per share) \| $ / shares		$ 0.75
Maturity period		5 years
Maturity date		Jun. 30, 2021
Percentage of liquidated damages payable		2.00%
Percentage of aggregate liquidated damages payable		12.00%
Interest rate payable on liquidated damages		12.00%
Percentage of issued and outstanding common stock payable upon conversion		9.99%
Sabby Management LLC and Broadfin LLC [Member] \| Senior Secured Notes Payable [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt		$ 10,000
Number of days for stockholders approval considered for maturity date		30 days
Interest rate		9.00%
Two Board Directors [Member]
Related Party Transaction [Line Items]
Up-front fee paid	$ 40,000
Monthly retainer fee		$ 10,000

Significant Customer Concentration (Details) - Customer Concentration Risk [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue [Member]
Product Information [Line Items]
Revenues	$ 6,093	$ 3,085
Concentration risk percentage	19.20%	16.70%
Accounts Receivable [Member]
Product Information [Line Items]
Accounts receivable	$ 585	$ 533
Concentration risk percentage	17.20%

Subsequent Events (Details) $ in Thousands				1 Months Ended	12 Months Ended
Subsequent Events (Details) $ in Thousands	Feb. 23, 2017 USD ($) shares	Jan. 27, 2017 USD ($) shares	Jan. 12, 2017 USD ($) shares	Mar. 17, 2017 Owners	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Subsequent Events [Line Items]
Debentures converted in shares of common stock, value					$ 265	$ 4,815
Subsequent Event [Member]
Subsequent Events [Line Items]
Debentures converted in shares of common stock, value	$ 19	$ 19	$ 19
Debentures converted in shares of common stock (in shares) \| shares	25,000	25,000	25,000
Number of device owners notified \| Owners				90